≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Adenocarcinoma of small intestine

EFO Endpoint Browser PheWeb

C3_SMALL_INTESTINE_ADENO

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Cancer registry: Topography ICD-O-3 — C17
  • Cancer registry: Morphology ICD-O-3 — 8140|8144|8145
  • Cancer registry: Behaviour codes — 3

1 out of 7 registries used, show all original rules.

109

4. Check minimum number of events

None

109

5. Include endpoints

None

109

6. Filter based on genotype QC (FinnGen only)

106

Control definitions (FinnGen only)

Control exclude
C3_CANCER, C3_CANCER_WIDE

Extra metadata

First used in FinnGen datafreeze
DF8

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

-FinnGen-

Key figures

All Female Male
Number of individuals 106 46 60
Unadjusted period prevalence (%) 0.02 0.02 0.03
Median age at first event (years) 68.63 66.48 70.27

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
109
Matched controls
1090
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
130
Kela drug reimbursment
Malignant tumour
+∞
93.7
76
*
A03FA01
ATC
metoclopramide; systemic, rectal
24.0
66.2
69
73
L01BC06
ATC
capecitabine; oral
+∞
64.0
55
*
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
31.4
53.8
39
19
C17.0
ICD-10 Finland
Malignant neoplasm: Duodenum
+∞
53.6
47
*
8140/3-C17.0
ICD-O-3
Adenocarcinoma, NOS, of duodenum
+∞
49.9
44
*
JFB00
NOMESCO Finland
Partial resection of small intestine
377.1
48.1
45
*
H02AB02
ATC
dexamethasone; systemic
188.4
45.9
45
*
JN4AD
NOMESCO Finland
Body CT examination
21.2
45.9
40
29
A04AA02
ATC
granisetron; systemic, transdermal
+∞
40.1
36
*
D37.2
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Small intestine
536.2
38.6
36
*
WX302
NOMESCO Finland
Thoracal epidural anesthesy
53.6
35.0
41
12
C17.1
ICD-10 Finland
Malignant neoplasm: Jejunum
+∞
34.2
31
*
JLC30
NOMESCO Finland
Pancreatoduodenectomy
+∞
34.2
31
*
C17.9
ICD-10 Finland
Malignant neoplasm: Small intestine, unspecified
+∞
34.2
31
*
JN3AD
NOMESCO Finland
Abdominal CT examination
10.7
31.1
44
65
Z51.5
ICD-10 Finland
Palliative care
15.1
30.8
31
28
8140/3-C17.9
ICD-O-3
Adenocarcinoma, NOS, of small intestine, NOS
+∞
30.7
28
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
30.7
28
*
K56.6
ICD-10 Finland
Other and unspecified intestinal obstruction
71.2
28.0
31
6
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
7.3
23.8
71
223
C17.2
ICD-10 Finland
Malignant neoplasm: Ileum
+∞
22.7
21
*
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
+∞
21.6
20
*
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
22.3
21.2
31
19
JN4BD
NOMESCO Finland
Extensive body CT
20.0
21.1
32
22
8140/3-C17.2
ICD-O-3
Adenocarcinoma, NOS, of ileum
+∞
20.4
19
*
TPH07
NOMESCO Finland
Cathetrisation of artery
7.6
19.6
34
61
N02AA05
ATC
oxycodone; systemic
6.5
19.6
44
103
133
Kela drug reimbursment
Severe chronic pancreatic insufficiency
47.9
19.5
23
6
A09AA02
ATC
multienzymes (lipase, protease etc.); oral
31.9
19.3
25
10
WX402
NOMESCO Finland
General anaesthesia
5.9
17.5
44
113
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
17.1
16
*
8140/3-C17.1
ICD-O-3
Adenocarcinoma, NOS, of jejunum
+∞
17.1
16
*
A04AA01
ATC
ondansetron; systemic, rectal
21.2
17.1
25
15
B01AB10
ATC
tinzaparin; parenteral
7.5
16.7
28
48
JAH00
NOMESCO Finland
Laparotomy
23.9
16.4
23
12
D50.9
ICD-10 Finland
Iron deficiency anaemia, unspecified
7.8
16.3
26
42
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
45.4
16.0
19
5
TPX10
NOMESCO Finland
Implantation of vascular injection port
34.5
15.8
20
7
JAH01
NOMESCO Finland
Laparoscopy
20.8
15.1
22
13
WX408
NOMESCO Finland
General anesthesy, balanced
4.9
14.3
45
137
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
39.8
14.0
17
5
WZC00
NOMESCO Finland
Treatment plan or consultation
4.6
13.9
52
181
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
+∞
13.8
13
*
A04AA55
ATC
palonosetron, combinations; systemic
+∞
13.8
13
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
159.0
13.8
14
*
D64.9
ICD-10 Finland
Anaemia, unspecified
5.6
13.1
30
69
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
+∞
12.7
12
*
C17.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of small intestine
+∞
12.7
12
*
UJF32
NOMESCO Finland
Coloscopy
4.3
12.5
47
162
JF1AB
NOMESCO Finland
Passage examination of small bowell with X-ray
53.0
12.2
14
*
R4190
NOMESCO Finland
Nutritional therapy
19.3
12.2
18
11
B01AB05
ATC
enoxaparin; parenteral
4.0
11.5
55
223
WZC30
NOMESCO Finland
Teaching
4.7
11.3
32
88
K56.7
ICD-10 Finland
Ileus, unspecified
24.5
11.0
15
7
ZX120
NOMESCO Finland
Intravenous
9.1
10.9
23
31
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
121.2
10.6
11
*
Z80.0
ICD-10 Finland
Family history of malignant neoplasm of digestive organs
121.2
10.6
11
*
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
+∞
10.6
10
*
C78.6
ICD-10 Finland
Secondary malignant neoplasm of retroperitoneum and peritoneum
+∞
10.6
10
*
K56.5
ICD-10 Finland
Intestinal adhesions [bands] with obstruction
26.5
10.5
14
6
JN3BD
NOMESCO Finland
Extensive abdominal CT
5.2
10.2
24
56
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
29.2
10.1
13
5
Z31.5
ICD-10 Finland
Genetic counselling
15.4
10.0
16
12
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
4.0
9.8
37
125
TPH04
NOMESCO Finland
Cathetrisation of vein
4.0
9.6
35
115
166
Kela drug reimbursment
Dalteparin and tinzaparin (treatment for more than 6 months)
+∞
9.5
9
*
ZXE20
NOMESCO Finland
More than three and less than five hours
4.4
9.3
28
80
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
3.4
9.2
56
257
D37.7
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Other digestive organs
26.7
9.1
12
5
D13.2
ICD-10 Finland
Benign neoplasm: Duodenum
26.7
9.1
12
5
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
4.5
8.9
25
67
601
Kela drug reimbursment
Severe malabsorption of nutrients, mainly fats
30.2
8.7
11
*
WX600
NOMESCO Finland
Single shot through catheter
97.3
8.5
9
*
XX3DW
NOMESCO Finland
Time consuming IT work
9.4
8.5
17
21
ZXD05
NOMESCO Finland
Urgent procedure
3.3
8.5
47
202
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
8.4
8
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
8.4
8
*
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
+∞
8.4
8
*
A79
ICPC
Malignancy NOS
+∞
8.4
8
*
Z04.8
ICD-10 Finland
Examination and observation for other specified reasons
3.9
7.9
27
84
R4110
NOMESCO Finland
Physiotherapy
3.2
7.8
44
189
A02BC02
ATC
pantoprazole; systemic
3.8
7.5
88
573
UJF92
NOMESCO Finland
Capsular endoscopy
17.3
7.4
11
7
JDE00
NOMESCO Finland
Gastrojejunostomy
+∞
7.4
7
*
L03AA02
ATC
filgrastim; parenteral
+∞
7.4
7
*
PJA12
NOMESCO Finland
Sentinel node biopsy
+∞
7.4
7
*
WB121
NOMESCO Finland
Demanding neoadjuvant cytostatic therapy
+∞
7.4
7
*
WB123
NOMESCO Finland
Demanding adjuvant cytostatic therapy
+∞
7.4
7
*
D77
ICPC
Malignant digestive neopl other/NOS
+∞
7.4
7
*
WD415
NOMESCO Finland
Demanding antibody therapy of methastized malignancy
+∞
7.4
7
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
7.4
7
*
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
+∞
7.4
7
*
115
Kela drug reimbursment
Breast cancer
+∞
7.4
7
*
A04AD12
ATC
aprepitant; systemic
+∞
7.4
7
*
WW500
NOMESCO Finland
Blood transfusion
13.3
7.3
12
10
JDW98
NOMESCO Finland
Other transluminal endoscopic operation on stomach or duodenum
32.4
7.3
9
*
JN3CD
NOMESCO Finland
Abdominal CT examination both without and with contrast
15.1
7.1
11
8
WX404
NOMESCO Finland
Intravenous generell anesthesy
3.4
6.9
30
109
TJD00
NOMESCO Finland
Insertion of nasogastric or naso-gastroduodenal tube
42.8
6.9
8
*
JA3AT
NOMESCO Finland
Cathetrisation of abdominal cavity with ultrasound guidance
42.8
6.9
8
*
ZXE00
NOMESCO Finland
One hour or less
2.9
6.8
53
270
UJF45
NOMESCO Finland
Flexible sigmoidoscopy with biopsy
4.6
6.6
17
42
ZXE30
NOMESCO Finland
More than five and less than seven hours
9.1
6.5
13
16
WF002
NOMESCO Finland
Radical radiotherapy
74.0
6.5
7
*
JJ2AT
NOMESCO Finland
Biopsy of liver with ultrasound guidance
74.0
6.5
7
*
D50.8
ICD-10 Finland
Other iron deficiency anaemias
19.4
6.4
9
5
C17
ICD-10 Finland
Malignant neoplasm of small intestine
+∞
6.3
6
*
C25.0
ICD-10 Finland
Malignant neoplasm: Head of pancreas
+∞
6.3
6
*
XZZ00
NOMESCO Finland
Active surveillance of a diagnosed cancer
+∞
6.3
6
*
XF603
NOMESCO Finland
Direct intraarterial blood pressure measurement
9.5
6.2
12
14
WX306
NOMESCO Finland
Lumbar epidural anesthesy
9.5
6.2
12
14
R11
ICD-10 Finland
Nausea and vomiting
3.9
6.2
20
59
ZXD10
NOMESCO Finland
Scheduled procedure
2.7
6.2
54
288
JN3AA
NOMESCO Finland
Abdominal X-ray examination without contrast
8.0
6.1
13
18
ZXE10
NOMESCO Finland
More than one and less than three hours
2.7
6.0
49
252

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Upper gastrointestinal surgery
106 [44777669]
1.0e+00
2.6e+00
—
1.0e+50
5.0e+00
4.5e+00
3.6e+00
cases:20.37%
controls:8.61%
cases:31.48%
controls:3.43%
—
—
cases:21.30%
controls:0.00%
cases:53.77%
controls:0.74%
cases:74.23%
controls:3.20%
cases:73.77%
controls:7.42%
22
93
86
987
34
37
74
1043
—
23
0
85
1080
57
8
49
1072
72
34
25
1030
45
65
16
811
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
3.8e-01
1.9e+00
4.4e+00
—
4.3e+00
3.2e+00
2.0e+00
cases:15.74%
controls:11.30%
cases:33.33%
controls:6.67%
cases:34.26%
controls:0.65%
—
—
cases:35.85%
controls:0.74%
cases:57.73%
controls:5.17%
cases:62.30%
controls:17.81%
17
122
91
958
36
72
72
1008
37
7
71
1073
—
38
8
68
1072
56
55
41
1009
38
156
23
720
Carcinoembryonic Ag [Mass/volume] in Serum or Plasma
2039-6 [3003785]
1.9e+00
3.3e+00
—
—
—
5.5e+00
5.0e+00
cases:4.63%
controls:0.74%
cases:11.11%
controls:0.46%
—
—
—
—
—
—
cases:58.76%
controls:0.56%
cases:63.93%
controls:1.14%
5
8
103
1072
12
5
96
1075
—
—
—
57
6
40
1058
39
10
22
866
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
4.7e-01
1.4e+00
3.5e+00
1.0e+50
4.0e+00
2.7e+00
1.6e+00
cases:16.67%
controls:11.11%
cases:19.44%
controls:5.83%
cases:25.00%
controls:1.02%
cases:5.56%
controls:0.00%
cases:27.36%
controls:0.65%
cases:49.48%
controls:6.30%
cases:52.46%
controls:18.26%
18
120
90
960
21
63
87
1017
27
11
81
1069
6
0
102
1080
29
7
77
1073
48
67
49
997
32
160
29
716
Outpatient Visit
OP [9202]
6.1e-01
8.8e-01
1.7e+00
3.6e+00
1.9e+00
1.6e+00
2.5e+00
cases:85.19%
controls:75.83%
cases:76.85%
controls:57.87%
cases:41.67%
controls:11.57%
cases:21.30%
controls:0.74%
cases:44.34%
controls:10.37%
cases:87.63%
controls:58.27%
cases:98.36%
controls:83.33%
92
819
16
261
83
625
25
455
45
125
63
955
23
8
85
1072
47
112
59
968
85
620
12
444
60
730
1
146
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
3.0e-01
1.5e+00
3.3e+00
—
3.6e+00
2.2e+00
1.4e+00
cases:28.70%
controls:23.06%
cases:38.89%
controls:12.59%
cases:40.74%
controls:2.41%
—
—
cases:36.79%
controls:1.57%
cases:58.76%
controls:13.16%
cases:65.57%
controls:31.62%
31
249
77
831
42
136
66
944
44
26
64
1054
—
39
17
67
1063
57
140
40
924
40
277
21
599
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
1.2e+00
2.8e+00
—
—
—
5.2e+00
3.6e+00
cases:4.63%
controls:1.48%
cases:7.41%
controls:0.46%
—
—
—
—
—
—
cases:51.55%
controls:0.56%
cases:31.15%
controls:1.26%
5
16
103
1064
8
5
100
1075
—
—
—
50
6
47
1058
19
11
42
865
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
1.0e+00
2.1e+00
2.9e+00
—
2.5e+00
1.9e+00
8.9e-01
cases:15.74%
controls:6.39%
cases:30.56%
controls:5.09%
cases:12.96%
controls:0.83%
—
—
cases:6.60%
controls:0.56%
cases:21.65%
controls:4.04%
cases:29.51%
controls:14.73%
17
69
91
1011
33
55
75
1025
14
9
94
1071
—
7
6
99
1074
21
43
76
1021
18
129
43
747
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
6.9e-01
1.4e+00
2.3e+00
—
2.5e+00
2.5e+00
1.4e+00
cases:23.15%
controls:13.15%
cases:25.93%
controls:7.87%
cases:18.52%
controls:2.13%
—
—
cases:17.92%
controls:1.76%
cases:50.52%
controls:7.61%
cases:49.18%
controls:19.52%
25
142
83
938
28
85
80
995
20
23
88
1057
—
19
19
87
1061
49
81
48
983
30
171
31
705
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
1.0e-01
1.8e+00
—
—
3.8e+00
3.1e+00
1.5e+00
cases:8.33%
controls:7.59%
cases:17.59%
controls:3.33%
—
—
—
—
cases:16.98%
controls:0.46%
cases:31.96%
controls:2.07%
cases:31.15%
controls:9.59%
9
82
99
998
19
36
89
1044
—
—
18
5
88
1075
31
22
66
1042
19
84
42
792
Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]
1.5e+00
2.1e+00
—
—
2.4e+00
2.6e+00
1.5e+00
cases:9.26%
controls:2.22%
cases:12.04%
controls:1.67%
—
—
—
—
cases:4.72%
controls:0.46%
cases:17.53%
controls:1.50%
cases:18.03%
controls:4.68%
10
24
98
1056
13
18
95
1062
—
—
5
5
101
1075
17
16
80
1048
11
41
50
835
Inpatient Hospital
21 [8717]
7.0e-01
8.9e-01
3.7e+00
—
3.3e+00
1.4e+00
9.0e-01
cases:49.07%
controls:32.31%
cases:24.07%
controls:11.48%
cases:37.04%
controls:1.48%
—
—
cases:28.30%
controls:1.48%
cases:31.96%
controls:10.24%
cases:36.07%
controls:18.72%
53
349
55
731
26
124
82
956
40
16
68
1064
—
30
16
76
1064
31
109
66
955
22
164
39
712
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
0.0e+00
6.9e-01
3.8e+00
—
2.9e+00
1.9e+00
1.2e+00
cases:15.74%
controls:15.74%
cases:18.52%
controls:10.28%
cases:26.85%
controls:0.83%
—
—
cases:16.98%
controls:1.11%
cases:42.27%
controls:9.68%
cases:49.18%
controls:22.95%
17
170
91
910
20
111
88
969
29
9
79
1071
—
18
12
88
1068
41
103
56
961
30
201
31
675
Internal Medicine
11 [38004456]
4.3e-01
1.7e+00
2.8e+00
—
2.3e+00
1.8e+00
9.9e-01
cases:34.26%
controls:25.28%
cases:34.26%
controls:9.07%
cases:18.52%
controls:1.39%
—
—
cases:12.26%
controls:1.39%
cases:37.11%
controls:9.02%
cases:42.62%
controls:21.69%
37
273
71
807
37
98
71
982
20
15
88
1065
—
13
15
93
1065
36
96
61
968
26
190
35
686
loperamide oxide; oral
A07DA05 [21600648]
2.0e+00
—
—
—
—
3.8e+00
3.4e+00
cases:7.41%
controls:1.02%
—
—
—
—
—
—
—
—
cases:25.77%
controls:0.75%
cases:21.31%
controls:0.91%
8
11
100
1069
—
—
—
—
25
8
72
1056
13
8
48
868
loperamide; oral
A07DA03 [21600646]
2.0e+00
—
—
—
—
3.8e+00
3.4e+00
cases:7.41%
controls:1.02%
—
—
—
—
—
—
—
—
cases:25.77%
controls:0.75%
cases:21.31%
controls:0.91%
8
11
100
1069
—
—
—
—
25
8
72
1056
13
8
48
868
Laboratory Visit
OMOP4822461 [32036]
5.2e-02
2.9e-01
2.2e+00
4.8e+00
2.1e+00
4.5e-01
2.0e-01
cases:55.56%
controls:54.26%
cases:58.33%
controls:51.20%
cases:60.19%
controls:14.91%
cases:50.93%
controls:0.83%
cases:60.38%
controls:15.46%
cases:64.95%
controls:54.23%
cases:73.77%
controls:69.63%
60
586
48
494
63
553
45
527
65
161
43
919
55
9
53
1071
64
167
42
913
63
577
34
487
45
610
16
266
Outpatient Hospital
22 [8756]
5.8e-01
6.6e-01
3.8e+00
—
3.6e+00
1.7e+00
8.8e-01
cases:38.89%
controls:26.20%
cases:15.74%
controls:8.80%
cases:29.63%
controls:0.93%
—
—
cases:23.58%
controls:0.83%
cases:25.77%
controls:6.20%
cases:26.23%
controls:12.90%
42
283
66
797
17
95
91
985
32
10
76
1070
—
25
9
81
1071
25
66
72
998
16
113
45
763
Prealbumin [Mass/volume] in Serum or Plasma
14338-8 [3013742]
—
2.1e+00
—
—
—
3.8e+00
3.0e+00
—
—
cases:5.56%
controls:0.74%
—
—
—
—
—
—
cases:25.77%
controls:0.75%
cases:27.87%
controls:1.94%
—
6
8
102
1072
—
—
—
25
8
72
1056
17
17
44
859
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
7.0e-01
1.5e+00
—
1.0e+50
3.0e+00
2.7e+00
1.6e+00
cases:14.81%
controls:7.96%
cases:14.81%
controls:3.89%
—
—
cases:7.41%
controls:0.00%
cases:13.21%
controls:0.74%
cases:38.14%
controls:4.14%
cases:39.34%
controls:11.19%
16
86
92
994
16
42
92
1038
—
8
0
100
1080
14
8
92
1072
37
44
60
1020
24
98
37
778
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]
1.2e+00
3.1e+00
1.0e+50
1.0e+50
1.0e+50
2.3e+00
2.1e+00
cases:14.81%
controls:4.91%
cases:25.00%
controls:1.48%
cases:12.96%
controls:0.00%
cases:11.11%
controls:0.00%
cases:6.60%
controls:0.00%
cases:13.40%
controls:1.50%
cases:22.95%
controls:3.42%
16
53
92
1027
27
16
81
1064
14
0
94
1080
12
0
96
1080
7
0
99
1080
13
16
84
1048
14
30
47
846
Emergency Room Visit
ER [9203]
3.2e-01
1.3e+00
3.6e+00
—
2.0e+00
1.8e+00
8.9e-01
cases:41.67%
controls:34.17%
cases:37.04%
controls:13.98%
cases:37.04%
controls:1.57%
—
—
cases:12.26%
controls:1.85%
cases:44.33%
controls:11.18%
cases:47.54%
controls:27.05%
45
369
63
711
40
151
68
929
40
17
68
1063
—
13
20
93
1060
43
119
54
945
29
237
32
639
General Surgery
2 [38004447]
2.6e-01
1.1e+00
3.3e+00
—
2.7e+00
1.6e+00
9.7e-01
cases:19.44%
controls:15.74%
cases:12.96%
controls:4.81%
cases:16.67%
controls:0.74%
—
—
cases:16.04%
controls:1.30%
cases:21.65%
controls:5.08%
cases:26.23%
controls:11.87%
21
170
87
910
14
52
94
1028
18
8
90
1072
—
17
14
89
1066
21
54
76
1010
16
104
45
772
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
9.1e-02
2.3e-01
2.3e+00
1.0e+50
2.8e+00
2.3e+00
1.1e+00
cases:12.04%
controls:11.11%
cases:8.33%
controls:6.76%
cases:11.11%
controls:1.20%
cases:11.11%
controls:0.00%
cases:12.26%
controls:0.83%
cases:36.08%
controls:5.17%
cases:40.98%
controls:19.18%
13
120
95
960
9
73
99
1007
12
13
96
1067
12
0
96
1080
13
9
93
1071
35
55
62
1009
25
168
36
708
Abdominal CT examination
JN3AD [2001305554]
-1.0e+50
2.6e+00
1.0e+50
—
—
3.3e+00
2.5e+00
cases:0.00%
controls:1.02%
cases:8.33%
controls:0.65%
cases:9.26%
controls:0.00%
—
—
—
—
cases:15.46%
controls:0.66%
cases:19.67%
controls:2.05%
0
11
108
1069
9
7
99
1073
10
0
98
1080
—
—
15
7
82
1057
12
18
49
858
Amylase.pancreatic [Enzymatic activity/volume] in Serum or Plasma
1805-1 [3016417]
—
2.9e+00
—
—
—
3.4e+00
2.1e+00
—
—
cases:11.11%
controls:0.65%
—
—
—
—
—
—
cases:21.65%
controls:0.94%
cases:19.67%
controls:2.97%
—
12
7
96
1073
—
—
—
21
10
76
1054
12
26
49
850
Bilirubin.conjugated [Moles/volume] in Serum or Plasma
29760-6 [3005772]
—
2.9e+00
—
—
—
3.2e+00
2.3e+00
—
—
cases:9.26%
controls:0.56%
—
—
—
—
—
—
cases:25.77%
controls:1.41%
cases:24.59%
controls:3.20%
—
10
6
98
1074
—
—
—
25
15
72
1049
15
28
46
848
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
5.3e-01
1.8e+00
2.4e+00
—
2.6e+00
1.6e+00
9.0e-01
cases:8.33%
controls:5.09%
cases:14.81%
controls:2.87%
cases:7.41%
controls:0.74%
—
—
cases:5.66%
controls:0.46%
cases:15.46%
controls:3.48%
cases:22.95%
controls:10.84%
9
55
99
1025
16
31
92
1049
8
8
100
1072
—
6
5
100
1075
15
37
82
1027
14
95
47
781
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
-5.5e-02
2.4e-01
2.2e+00
1.0e+50
3.0e+00
2.1e+00
1.0e+00
cases:11.11%
controls:11.67%
cases:9.26%
controls:7.41%
cases:11.11%
controls:1.39%
cases:11.11%
controls:0.00%
cases:14.15%
controls:0.83%
cases:35.05%
controls:6.30%
cases:42.62%
controls:21.12%
12
126
96
954
10
80
98
1000
12
15
96
1065
12
0
96
1080
15
9
91
1071
34
67
63
997
26
185
35
691
Emergency Room and Inpatient Visit
ERIP [262]
4.2e-01
1.4e+00
3.7e+00
—
—
2.1e+00
1.0e+00
cases:6.48%
controls:4.35%
cases:12.96%
controls:3.52%
cases:15.74%
controls:0.46%
—
—
—
—
cases:20.62%
controls:3.10%
cases:32.79%
controls:14.95%
7
47
101
1033
14
38
94
1042
17
5
91
1075
—
—
20
33
77
1031
20
131
41
745
Bacteria [Presence] in Urine
87829-8 [36304419]
6.6e-01
1.6e+00
2.2e+00
—
2.6e+00
1.6e+00
1.0e+00
cases:9.26%
controls:5.00%
cases:12.96%
controls:2.78%
cases:6.48%
controls:0.74%
—
—
cases:5.66%
controls:0.46%
cases:14.43%
controls:3.20%
cases:24.59%
controls:10.62%
10
54
98
1026
14
30
94
1050
7
8
101
1072
—
6
5
100
1075
14
34
83
1030
15
93
46
783
INR in Blood by Coagulation assay
34714-6 [3032080]
4.1e-01
8.0e-01
2.3e+00
—
2.3e+00
1.9e+00
1.5e+00
cases:19.44%
controls:13.80%
cases:19.44%
controls:9.81%
cases:25.00%
controls:3.15%
—
—
cases:23.58%
controls:2.87%
cases:41.24%
controls:9.49%
cases:49.18%
controls:18.26%
21
149
87
931
21
106
87
974
27
34
81
1046
—
25
31
81
1049
40
101
57
963
30
160
31
716
Monocytes/Leukocytes in Blood
26485-3 [3019069]
5.7e-01
1.2e+00
2.5e+00
—
1.8e+00
1.4e+00
1.1e+00
cases:18.52%
controls:11.39%
cases:18.52%
controls:6.39%
cases:12.96%
controls:1.20%
—
—
cases:6.60%
controls:1.11%
cases:22.68%
controls:6.58%
cases:36.07%
controls:16.44%
20
123
88
957
20
69
88
1011
14
13
94
1067
—
7
12
99
1068
22
70
75
994
22
144
39
732
Short blood count panel - Blood
55429-5 [40758558]
9.5e-01
1.5e+00
2.2e+00
—
2.2e+00
2.2e+00
8.3e-01
cases:14.81%
controls:6.30%
cases:11.11%
controls:2.78%
cases:5.56%
controls:0.65%
—
—
cases:7.55%
controls:0.93%
cases:23.71%
controls:3.38%
cases:18.03%
controls:8.79%
16
68
92
1012
12
30
96
1050
6
7
102
1073
—
8
10
98
1070
23
36
74
1028
11
77
50
799
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
5.9e-01
1.2e+00
2.5e+00
—
1.8e+00
1.4e+00
1.0e+00
cases:18.52%
controls:11.20%
cases:18.52%
controls:6.39%
cases:12.96%
controls:1.20%
—
—
cases:6.60%
controls:1.11%
cases:22.68%
controls:6.58%
cases:36.07%
controls:16.55%
20
121
88
959
20
69
88
1011
14
13
94
1067
—
7
12
99
1068
22
70
75
994
22
145
39
731
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
-1.6e-02
9.1e-01
2.8e+00
—
2.9e+00
1.3e+00
6.5e-01
cases:37.04%
controls:37.41%
cases:44.44%
controls:24.35%
cases:45.37%
controls:4.72%
—
—
cases:44.34%
controls:4.07%
cases:55.67%
controls:24.91%
cases:65.57%
controls:49.77%
40
404
68
676
48
263
60
817
49
51
59
1029
—
47
44
59
1036
54
265
43
799
40
436
21
440
Basophils/Leukocytes in Blood
30180-4 [3022096]
6.1e-01
1.2e+00
2.5e+00
—
1.8e+00
1.4e+00
9.7e-01
cases:18.52%
controls:11.02%
cases:18.52%
controls:6.30%
cases:12.96%
controls:1.20%
—
—
cases:6.60%
controls:1.11%
cases:22.68%
controls:6.58%
cases:34.43%
controls:16.67%
20
119
88
961
20
68
88
1012
14
13
94
1067
—
7
12
99
1068
22
70
75
994
21
146
40
730
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
6.9e-01
1.6e+00
2.2e+00
—
2.6e+00
1.5e+00
9.1e-01
cases:11.11%
controls:5.93%
cases:14.81%
controls:3.52%
cases:7.41%
controls:0.83%
—
—
cases:5.66%
controls:0.46%
cases:15.46%
controls:3.76%
cases:26.23%
controls:12.56%
12
64
96
1016
16
38
92
1042
8
9
100
1071
—
6
5
100
1075
15
40
82
1024
16
110
45
766
Leukocytes [#/volume] in Urine
30405-5 [3018095]
7.1e-01
1.5e+00
2.5e+00
—
2.6e+00
1.3e+00
9.7e-01
cases:12.04%
controls:6.30%
cases:14.81%
controls:3.80%
cases:9.26%
controls:0.83%
—
—
cases:5.66%
controls:0.46%
cases:15.46%
controls:4.61%
cases:29.51%
controls:13.70%
13
68
95
1012
16
41
92
1039
10
9
98
1071
—
6
5
100
1075
15
49
82
1015
18
120
43
756
Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]
1.3e+00
2.1e+00
—
—
2.4e+00
1.8e+00
9.8e-01
cases:14.81%
controls:4.72%
cases:23.15%
controls:3.43%
—
—
—
—
cases:4.72%
controls:0.46%
cases:16.49%
controls:3.01%
cases:21.31%
controls:9.25%
16
51
92
1029
25
37
83
1043
—
—
5
5
101
1075
16
32
81
1032
13
81
48
795
Basophils [#/volume] in Blood
26444-0 [3006315]
5.8e-01
1.4e+00
2.5e+00
—
2.0e+00
1.4e+00
8.0e-01
cases:19.44%
controls:11.94%
cases:22.22%
controls:6.67%
cases:13.89%
controls:1.30%
—
—
cases:7.55%
controls:1.11%
cases:21.65%
controls:6.67%
cases:32.79%
controls:18.04%
21
129
87
951
24
72
84
1008
15
14
93
1066
—
8
12
98
1068
21
71
76
993
20
158
41
718
Colonoscopy Study observation
28023-0 [3022145]
1.6e+00
1.8e+00
—
—
—
2.2e+00
1.6e+00
cases:8.33%
controls:1.76%
cases:8.33%
controls:1.48%
—
—
—
—
—
—
cases:7.22%
controls:0.85%
cases:16.39%
controls:3.88%
9
19
99
1061
9
16
99
1064
—
—
—
7
9
90
1055
10
34
51
842
Monocytes [#/volume] in Blood
26484-6 [3001604]
5.7e-01
1.3e+00
2.5e+00
—
2.0e+00
1.4e+00
8.0e-01
cases:19.44%
controls:12.04%
cases:21.30%
controls:6.67%
cases:13.89%
controls:1.30%
—
—
cases:7.55%
controls:1.11%
cases:21.65%
controls:6.67%
cases:32.79%
controls:17.92%
21
130
87
950
23
72
85
1008
15
14
93
1066
—
8
12
98
1068
21
71
76
993
20
157
41
719
pantoprazole; oral, parenteral
A02BC02 [21600097]
5.1e-01
1.2e+00
1.5e+00
—
1.7e+00
1.5e+00
1.2e+00
cases:27.78%
controls:18.70%
cases:33.33%
controls:13.15%
cases:13.89%
controls:3.61%
—
—
cases:14.15%
controls:2.78%
cases:38.14%
controls:12.22%
cases:49.18%
controls:22.72%
30
202
78
878
36
142
72
938
15
39
93
1041
—
15
30
91
1050
37
130
60
934
30
199
31
677
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
5.2e-01
1.3e+00
2.5e+00
—
1.9e+00
1.3e+00
7.4e-01
cases:19.44%
controls:12.50%
cases:22.22%
controls:6.94%
cases:13.89%
controls:1.30%
—
—
cases:7.55%
controls:1.20%
cases:21.65%
controls:6.77%
cases:32.79%
controls:18.84%
21
135
87
945
24
75
84
1005
15
14
93
1066
—
8
13
98
1067
21
72
76
992
20
165
41
711
Eosinophils [#/volume] in Blood
26449-9 [3013115]
5.7e-01
1.3e+00
2.4e+00
—
2.0e+00
1.3e+00
7.9e-01
cases:20.37%
controls:12.59%
cases:22.22%
controls:6.94%
cases:13.89%
controls:1.39%
—
—
cases:7.55%
controls:1.11%
cases:22.68%
controls:7.42%
cases:32.79%
controls:18.15%
22
136
86
944
24
75
84
1005
15
15
93
1065
—
8
12
98
1068
22
79
75
985
20
159
41
717
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
-3.6e-01
1.1e+00
2.6e+00
—
2.3e+00
1.0e+00
3.7e-01
cases:14.81%
controls:19.91%
cases:22.22%
controls:8.89%
cases:14.81%
controls:1.30%
—
—
cases:8.49%
controls:0.93%
cases:20.62%
controls:8.36%
cases:29.51%
controls:22.49%
16
215
92
865
24
96
84
984
16
14
92
1066
—
9
10
97
1070
20
89
77
975
18
197
43
679
pH of Serum or Plasma
2753-2 [3018418]
-2.1e-01
3.3e-01
2.2e+00
—
2.7e+00
2.0e+00
7.6e-01
cases:5.56%
controls:6.76%
cases:6.48%
controls:4.72%
cases:5.56%
controls:0.65%
—
—
cases:6.60%
controls:0.46%
cases:18.56%
controls:3.01%
cases:22.95%
controls:12.21%
6
73
102
1007
7
51
101
1029
6
7
102
1073
—
7
5
99
1075
18
32
79
1032
14
107
47
769
Normoblasts [#/volume] in Blood
715-3 [3021589]
4.3e-01
1.0e+00
2.6e+00
—
1.9e+00
1.2e+00
5.6e-01
cases:13.89%
controls:9.54%
cases:19.44%
controls:7.87%
cases:16.67%
controls:1.48%
—
—
cases:11.32%
controls:1.85%
cases:25.77%
controls:9.59%
cases:27.87%
controls:18.15%
15
103
93
977
21
85
87
995
18
16
90
1064
—
12
20
94
1060
25
102
72
962
17
159
44
717
Bacteria identified in Blood by Culture
600-7 [3023368]
2.2e-01
4.0e-01
2.5e+00
—
—
2.6e+00
1.6e+00
cases:6.48%
controls:5.28%
cases:4.63%
controls:3.15%
cases:5.56%
controls:0.46%
—
—
—
—
cases:29.90%
controls:3.10%
cases:32.79%
controls:9.25%
7
57
101
1023
5
34
103
1046
6
5
102
1075
—
—
29
33
68
1031
20
81
41
795
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
8.9e-02
6.3e-01
2.9e+00
—
2.8e+00
8.4e-01
3.3e-01
cases:47.22%
controls:45.00%
cases:50.93%
controls:35.56%
cases:50.93%
controls:5.56%
—
—
cases:51.89%
controls:6.02%
cases:60.82%
controls:40.23%
cases:68.85%
controls:61.30%
51
486
57
594
55
384
53
696
55
60
53
1020
—
55
65
51
1015
59
428
38
636
42
537
19
339
12 lead EKG panel
34534-8 [3044889]
1.7e-01
2.0e-01
3.0e+00
—
2.4e+00
1.1e+00
4.5e-01
cases:29.63%
controls:26.20%
cases:18.52%
controls:15.65%
cases:21.30%
controls:1.30%
—
—
cases:16.04%
controls:1.67%
cases:34.02%
controls:15.04%
cases:40.98%
controls:30.71%
32
283
76
797
20
169
88
911
23
14
85
1066
—
17
18
89
1062
33
160
64
904
25
269
36
607
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
8.2e-02
6.3e-01
2.8e+00
—
2.8e+00
7.9e-01
3.3e-01
cases:47.22%
controls:45.19%
cases:50.93%
controls:35.56%
cases:50.93%
controls:5.74%
—
—
cases:51.89%
controls:6.02%
cases:59.79%
controls:40.41%
cases:68.85%
controls:61.42%
51
488
57
592
55
384
53
696
55
62
53
1018
—
55
65
51
1015
58
430
39
634
42
538
19
338
dexamethasone; oral, parenteral
H02AB02 [21602730]
—
—
—
—
—
4.3e+00
2.1e+00
—
—
—
—
—
—
—
—
—
—
cases:29.90%
controls:0.56%
cases:19.67%
controls:2.97%
—
—
—
—
—
29
6
68
1058
12
26
49
850
Iron/Transferrin [Ratio] in Serum or Plasma
60517-0 [40763571]
1.4e+00
2.1e+00
—
—
—
2.8e+00
1.5e+00
cases:7.41%
controls:1.94%
cases:11.11%
controls:1.48%
—
—
—
—
—
—
cases:17.53%
controls:1.32%
cases:16.39%
controls:4.22%
8
21
100
1059
12
16
96
1064
—
—
—
17
14
80
1050
10
37
51
839
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
3.3e-02
6.0e-01
2.7e+00
—
2.8e+00
7.5e-01
3.5e-01
cases:48.15%
controls:47.31%
cases:54.63%
controls:39.91%
cases:55.56%
controls:7.50%
—
—
cases:54.72%
controls:6.94%
cases:61.86%
controls:43.33%
cases:72.13%
controls:64.61%
52
511
56
569
59
431
49
649
60
81
48
999
—
58
75
48
1005
60
461
37
603
44
566
17
310
Anaemia, unspecified
D64.9 [45600610]
1.3e+00
3.4e+00
1.0e+50
—
—
2.9e+00
—
cases:4.63%
controls:1.30%
cases:13.89%
controls:0.56%
cases:7.41%
controls:0.00%
—
—
—
—
cases:9.28%
controls:0.56%
—
—
5
14
103
1066
15
6
93
1074
8
0
100
1080
—
—
9
6
88
1058
—
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
1.5e+00
2.1e+00
—
—
—
2.6e+00
1.5e+00
cases:8.33%
controls:2.04%
cases:12.04%
controls:1.67%
—
—
—
—
—
—
cases:16.49%
controls:1.41%
cases:18.03%
controls:4.68%
9
22
99
1058
13
18
95
1062
—
—
—
16
15
81
1049
11
41
50
835
Inpatient Visit
IP [9201]
5.0e-01
7.2e-01
—
1.0e+50
2.2e+00
2.7e+00
1.3e+00
cases:9.26%
controls:5.83%
cases:5.56%
controls:2.78%
—
—
cases:14.81%
controls:0.00%
cases:5.66%
controls:0.65%
cases:27.84%
controls:2.63%
cases:34.43%
controls:12.21%
10
63
98
1017
6
30
102
1050
—
16
0
92
1080
6
7
100
1073
27
28
70
1036
21
107
40
769
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
5.0e-01
1.1e+00
2.6e+00
—
1.8e+00
1.5e+00
9.9e-01
cases:17.59%
controls:11.48%
cases:17.59%
controls:6.67%
cases:12.96%
controls:1.11%
—
—
cases:6.60%
controls:1.20%
cases:22.68%
controls:6.20%
cases:36.07%
controls:17.35%
19
124
89
956
19
72
89
1008
14
12
94
1068
—
7
13
99
1067
22
66
75
998
22
152
39
724
CBC panel - Blood by Automated count
58410-2 [40761511]
3.4e-02
5.2e-01
2.7e+00
—
2.6e+00
8.2e-01
4.7e-01
cases:44.44%
controls:43.61%
cases:41.67%
controls:29.91%
cases:41.67%
controls:4.72%
—
—
cases:42.45%
controls:5.19%
cases:50.52%
controls:31.11%
cases:62.30%
controls:50.91%
48
471
60
609
45
323
63
757
45
51
63
1029
—
45
56
61
1024
49
331
48
733
38
446
23
430
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
5.2e-01
1.0e+00
2.5e+00
—
1.6e+00
1.4e+00
1.0e+00
cases:17.59%
controls:11.30%
cases:16.67%
controls:6.67%
cases:12.96%
controls:1.20%
—
—
cases:5.66%
controls:1.20%
cases:22.68%
controls:6.48%
cases:36.07%
controls:16.67%
19
122
89
958
18
72
90
1008
14
13
94
1067
—
6
13
100
1067
22
69
75
995
22
146
39
730
Supplier / Service Provider
OMOP5117446 [33004]
-7.0e-01
-2.5e-01
—
—
—
3.7e+00
2.3e+00
cases:15.74%
controls:27.31%
cases:7.41%
controls:9.35%
—
—
—
—
—
—
cases:23.71%
controls:0.75%
cases:16.39%
controls:1.94%
17
295
91
785
8
101
100
979
—
—
—
23
8
74
1056
10
17
51
859
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
1.9e-01
6.0e-01
2.5e+00
—
2.5e+00
9.6e-01
5.9e-01
cases:33.33%
controls:29.26%
cases:38.89%
controls:25.83%
cases:37.04%
controls:4.72%
—
—
cases:38.68%
controls:4.81%
cases:51.55%
controls:29.04%
cases:65.57%
controls:51.37%
36
316
72
764
42
279
66
801
40
51
68
1029
—
41
52
65
1028
50
309
47
755
40
450
21
426
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
-7.5e-03
5.9e-01
2.4e+00
—
2.6e+00
9.4e-01
3.7e-01
cases:44.44%
controls:44.63%
cases:49.07%
controls:34.72%
cases:40.74%
controls:5.74%
—
—
cases:39.62%
controls:4.72%
cases:59.79%
controls:36.75%
cases:70.49%
controls:62.33%
48
482
60
598
53
375
55
705
44
62
64
1018
—
42
51
64
1029
58
391
39
673
43
546
18
330
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
8.3e-01
1.4e+00
—
1.0e+50
—
2.7e+00
1.8e+00
cases:12.04%
controls:5.65%
cases:10.19%
controls:2.59%
—
—
cases:6.48%
controls:0.00%
—
—
cases:29.90%
controls:2.82%
cases:32.79%
controls:7.42%
13
61
95
1019
11
28
97
1052
—
7
0
101
1080
—
29
30
68
1034
20
65
41
811
Other and unspecified abdominal pain
R10.4 [45568113]
6.9e-01
2.8e+00
—
—
—
1.7e+00
1.4e+00
cases:10.19%
controls:5.37%
cases:20.37%
controls:1.57%
—
—
—
—
—
—
cases:8.25%
controls:1.60%
cases:16.39%
controls:4.45%
11
58
97
1022
22
17
86
1063
—
—
—
8
17
89
1047
10
39
51
837
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
9.5e-01
1.5e+00
1.0e+50
1.0e+50
—
2.6e+00
1.7e+00
cases:9.26%
controls:3.80%
cases:8.33%
controls:1.94%
cases:19.44%
controls:0.00%
cases:4.63%
controls:0.00%
—
—
cases:24.74%
controls:2.44%
cases:26.23%
controls:5.82%
10
41
98
1039
9
21
99
1059
21
0
87
1080
5
0
103
1080
—
24
26
73
1038
16
51
45
825
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
1.1e-01
6.5e-01
2.5e+00
—
2.6e+00
7.4e-01
2.1e-01
cases:31.48%
controls:29.07%
cases:39.81%
controls:25.65%
cases:42.59%
controls:5.74%
—
—
cases:42.45%
controls:5.37%
cases:46.39%
controls:29.32%
cases:50.82%
controls:45.55%
34
314
74
766
43
277
65
803
46
62
62
1018
—
45
58
61
1022
45
312
52
752
31
399
30
477
Differential panel, method unspecified - Blood
69738-3 [42870588]
5.0e-01
1.4e+00
2.7e+00
—
2.0e+00
1.6e+00
8.2e-01
cases:12.04%
controls:7.69%
cases:14.81%
controls:4.07%
cases:10.19%
controls:0.74%
—
—
cases:5.66%
controls:0.83%
cases:19.59%
controls:4.70%
cases:22.95%
controls:11.64%
13
83
95
997
16
44
92
1036
11
8
97
1072
—
6
9
100
1071
19
50
78
1014
14
102
47
774
Teaching
WZC30 [2001310891]
—
—
—
—
—
3.4e+00
2.3e+00
—
—
—
—
—
—
—
—
—
—
cases:20.62%
controls:0.85%
cases:14.75%
controls:1.71%
—
—
—
—
—
20
9
77
1055
9
15
52
861
Case Management Agency
251B00000X [38004193]
1.0e-01
2.0e-01
1.2e+00
1.7e+00
1.7e+00
1.1e+00
2.1e-01
cases:74.07%
controls:72.04%
cases:71.30%
controls:67.13%
cases:56.48%
controls:27.96%
cases:9.26%
controls:1.76%
cases:66.04%
controls:26.85%
cases:85.57%
controls:66.92%
cases:85.25%
controls:82.42%
80
778
28
302
77
725
31
355
61
302
47
778
10
19
98
1061
70
290
36
790
83
712
14
352
52
722
9
154
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
1.0e-01
5.1e-01
2.2e+00
—
1.9e+00
1.3e+00
6.9e-01
cases:21.30%
controls:19.63%
cases:15.74%
controls:10.09%
cases:14.81%
controls:1.85%
—
—
cases:7.55%
controls:1.20%
cases:28.87%
controls:9.59%
cases:40.98%
controls:25.80%
23
212
85
868
17
109
91
971
16
20
92
1060
—
8
13
98
1067
28
102
69
962
25
226
36
650
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
-1.7e-02
1.3e+00
—
1.0e+50
—
2.5e+00
1.6e+00
cases:5.56%
controls:5.65%
cases:11.11%
controls:3.24%
—
—
cases:6.48%
controls:0.00%
—
—
cases:28.87%
controls:3.10%
cases:32.79%
controls:9.13%
6
61
102
1019
12
35
96
1045
—
7
0
101
1080
—
28
33
69
1031
20
80
41
796
Gastroenterology
10 [38004455]
8.8e-01
1.9e+00
—
1.0e+50
—
2.1e+00
1.4e+00
cases:13.89%
controls:6.30%
cases:21.30%
controls:3.80%
—
—
cases:6.48%
controls:0.00%
—
—
cases:19.59%
controls:2.91%
cases:22.95%
controls:6.85%
15
68
93
1012
23
41
85
1039
—
7
0
101
1080
—
19
31
78
1033
14
60
47
816
MCH [Entitic mass]
28539-5 [3035941]
3.7e-03
5.6e-01
2.7e+00
—
2.7e+00
6.9e-01
2.8e-01
cases:50.00%
controls:49.91%
cases:55.56%
controls:41.76%
cases:58.33%
controls:8.80%
—
—
cases:57.55%
controls:8.43%
cases:62.89%
controls:45.96%
cases:72.13%
controls:66.10%
54
539
54
541
60
451
48
629
63
95
45
985
—
61
91
45
989
61
489
36
575
44
579
17
297
Leukocytes [#/volume] in Blood
26464-8 [3010813]
4.1e-02
5.5e-01
2.7e+00
—
2.7e+00
6.9e-01
2.8e-01
cases:50.93%
controls:49.91%
cases:55.56%
controls:41.85%
cases:58.33%
controls:8.80%
—
—
cases:57.55%
controls:8.43%
cases:62.89%
controls:45.86%
cases:72.13%
controls:66.21%
55
539
53
541
60
452
48
628
63
95
45
985
—
61
91
45
989
61
488
36
576
44
580
17
296
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
-3.7e-03
5.5e-01
2.7e+00
—
2.7e+00
6.9e-01
2.8e-01
cases:50.00%
controls:50.09%
cases:55.56%
controls:41.85%
cases:58.33%
controls:8.80%
—
—
cases:57.55%
controls:8.52%
cases:62.89%
controls:45.96%
cases:72.13%
controls:66.21%
54
541
54
539
60
452
48
628
63
95
45
985
—
61
92
45
988
61
489
36
575
44
580
17
296
Platelets [#/volume] in Blood
26515-7 [3007461]
7.4e-03
5.5e-01
2.7e+00
—
2.7e+00
6.6e-01
2.8e-01
cases:50.00%
controls:49.81%
cases:55.56%
controls:41.85%
cases:58.33%
controls:8.80%
—
—
cases:57.55%
controls:8.52%
cases:61.86%
controls:45.68%
cases:72.13%
controls:66.21%
54
538
54
542
60
452
48
628
63
95
45
985
—
61
92
45
988
60
486
37
578
44
580
17
296
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
-7.4e-03
5.5e-01
2.7e+00
—
2.7e+00
6.9e-01
2.8e-01
cases:50.00%
controls:50.19%
cases:55.56%
controls:41.85%
cases:58.33%
controls:8.80%
—
—
cases:57.55%
controls:8.52%
cases:62.89%
controls:46.05%
cases:72.13%
controls:66.21%
54
542
54
538
60
452
48
628
63
95
45
985
—
61
92
45
988
61
490
36
574
44
580
17
296
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
-7.4e-03
5.5e-01
2.7e+00
—
2.7e+00
6.9e-01
2.8e-01
cases:50.00%
controls:50.19%
cases:55.56%
controls:41.85%
cases:58.33%
controls:8.80%
—
—
cases:57.55%
controls:8.52%
cases:62.89%
controls:45.96%
cases:72.13%
controls:66.21%
54
542
54
538
60
452
48
628
63
95
45
985
—
61
92
45
988
61
489
36
575
44
580
17
296
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
-7.4e-03
5.5e-01
2.7e+00
—
2.7e+00
6.9e-01
2.8e-01
cases:50.00%
controls:50.19%
cases:55.56%
controls:41.85%
cases:58.33%
controls:8.80%
—
—
cases:57.55%
controls:8.52%
cases:62.89%
controls:45.96%
cases:72.13%
controls:66.10%
54
542
54
538
60
452
48
628
63
95
45
985
—
61
92
45
988
61
489
36
575
44
579
17
297
Treatment plan or consultation
WZC00 [2001310885]
4.2e-01
—
—
—
—
3.4e+00
1.9e+00
cases:6.48%
controls:4.35%
—
—
—
—
—
—
—
—
cases:29.90%
controls:1.41%
cases:26.23%
controls:5.14%
7
47
101
1033
—
—
—
—
29
15
68
1049
16
45
45
831
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
4.8e-01
1.2e+00
2.4e+00
—
2.2e+00
1.6e+00
8.8e-01
cases:12.04%
controls:7.78%
cases:13.89%
controls:4.54%
cases:9.26%
controls:0.93%
—
—
cases:4.72%
controls:0.56%
cases:19.59%
controls:4.51%
cases:27.87%
controls:13.81%
13
84
95
996
15
49
93
1031
10
10
98
1070
—
5
6
101
1074
19
48
78
1016
17
121
44
755
Emergency Medicine
93 [38004510]
4.2e-01
9.2e-01
2.8e+00
—
1.4e+00
1.2e+00
6.4e-01
cases:20.37%
controls:14.35%
cases:21.30%
controls:9.72%
cases:19.44%
controls:1.39%
—
—
cases:4.72%
controls:1.20%
cases:26.80%
controls:9.77%
cases:42.62%
controls:28.08%
22
155
86
925
23
105
85
975
21
15
87
1065
—
5
13
101
1067
26
104
71
960
26
246
35
630
Office Visit
OMOP4822458 [581477]
2.2e-01
1.1e+00
—
—
3.0e+00
2.0e+00
—
cases:10.19%
controls:8.33%
cases:6.48%
controls:2.22%
—
—
—
—
cases:8.49%
controls:0.46%
cases:15.46%
controls:2.44%
—
—
11
90
97
990
7
24
101
1056
—
—
9
5
97
1075
15
26
82
1038
—
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
1.9e-01
6.9e-01
1.6e+00
—
2.2e+00
9.3e-01
6.6e-01
cases:24.07%
controls:20.74%
cases:21.30%
controls:11.94%
cases:10.19%
controls:2.13%
—
—
cases:10.38%
controls:1.20%
cases:23.71%
controls:10.90%
cases:42.62%
controls:27.74%
26
224
82
856
23
129
85
951
11
23
97
1057
—
11
13
95
1067
23
116
74
948
26
243
35
633
oxycodone; oral, parenteral
N02AA05 [21604260]
—
—
—
—
—
2.4e+00
2.4e+00
—
—
—
—
—
—
—
—
—
—
cases:12.37%
controls:1.32%
cases:24.59%
controls:2.74%
—
—
—
—
—
12
14
85
1050
15
24
46
852
esomeprazole; oral, parenteral
A02BC05 [21600100]
5.1e-01
1.3e+00
2.3e+00
—
1.3e+00
1.2e+00
5.9e-01
cases:14.81%
controls:9.44%
cases:18.52%
controls:6.11%
cases:5.56%
controls:0.56%
—
—
cases:5.66%
controls:1.57%
cases:16.49%
controls:5.83%
cases:16.39%
controls:9.82%
16
102
92
978
20
66
88
1014
6
6
102
1074
—
6
17
100
1063
16
62
81
1002
10
86
51
790
Cathetrisation of vein
TPH04 [2001309597]
3.7e-01
2.0e+00
—
—
—
2.8e+00
1.2e+00
cases:4.63%
controls:3.24%
cases:7.41%
controls:1.11%
—
—
—
—
—
—
cases:12.37%
controls:0.85%
cases:11.48%
controls:3.88%
5
35
103
1045
8
12
100
1068
—
—
—
12
9
85
1055
7
34
54
842
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
5.0e-01
1.2e+00
—
—
1.0e+50
2.8e+00
1.9e+00
cases:4.63%
controls:2.87%
cases:4.63%
controls:1.48%
—
—
—
—
cases:6.60%
controls:0.00%
cases:17.53%
controls:1.22%
cases:24.59%
controls:4.57%
5
31
103
1049
5
16
103
1064
—
—
7
0
99
1080
17
13
80
1051
15
40
46
836
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
1.5e-01
4.4e-01
2.4e+00
—
2.4e+00
6.4e-01
2.2e-01
cases:39.81%
controls:36.39%
cases:39.81%
controls:29.81%
cases:42.59%
controls:6.57%
—
—
cases:39.62%
controls:5.65%
cases:46.39%
controls:31.30%
cases:54.10%
controls:48.63%
43
393
65
687
43
322
65
758
46
71
62
1009
—
42
61
64
1019
45
333
52
731
33
426
28
450
tinzaparin; parenteral
B01AB10 [21600981]
—
—
—
—
1.0e+50
2.7e+00
2.0e+00
—
—
—
—
—
—
—
—
cases:7.55%
controls:0.00%
cases:9.28%
controls:0.66%
cases:11.48%
controls:1.71%
—
—
—
—
8
0
98
1080
9
7
88
1057
7
15
54
861
Chloride [Moles/volume] in Serum or Plasma
2075-0 [3014576]
8.0e-01
—
—
1.0e+50
—
3.3e+00
1.4e+00
cases:4.63%
controls:2.13%
—
—
—
—
cases:13.89%
controls:0.00%
—
—
cases:22.68%
controls:1.03%
cases:18.03%
controls:5.14%
5
23
103
1057
—
—
15
0
93
1080
—
22
11
75
1053
11
45
50
831
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]
—
2.3e+00
—
—
—
2.3e+00
1.1e+00
—
—
cases:4.63%
controls:0.46%
—
—
—
—
—
—
cases:7.22%
controls:0.75%
cases:8.20%
controls:2.97%
—
5
5
103
1075
—
—
—
7
8
90
1056
5
26
56
850
General anaesthesia
WX402 [2001310806]
—
—
—
1.0e+50
—
3.1e+00
1.5e+00
—
—
—
—
—
—
cases:12.04%
controls:0.00%
—
—
cases:16.49%
controls:0.85%
cases:14.75%
controls:3.65%
—
—
—
13
0
95
1080
—
16
9
81
1055
9
32
52
844
Bacteria identified in Isolate by Culture
43409-2 [3042936]
—
—
—
1.0e+50
—
2.9e+00
1.6e+00
—
—
—
—
—
—
cases:6.48%
controls:0.00%
—
—
cases:16.49%
controls:1.03%
cases:16.39%
controls:3.88%
—
—
—
7
0
101
1080
—
16
11
81
1053
10
34
51
842
Thorax X-ray examination
GD1AA [2001303617]
9.3e-01
9.2e-01
—
—
—
2.4e+00
1.1e+00
cases:23.15%
controls:10.65%
cases:9.26%
controls:3.89%
—
—
—
—
—
—
cases:24.74%
controls:2.82%
cases:29.51%
controls:11.99%
25
115
83
965
10
42
98
1038
—
—
—
24
30
73
1034
18
105
43
771
Cancer Ag 19-9 [Units/volume] in Serum or Plasma
24108-3 [3022914]
—
—
—
—
—
—
4.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:37.70%
controls:0.68%
—
—
—
—
—
—
23
6
38
870
enoxaparin; parenteral
B01AB05 [21600976]
-4.6e-01
—
—
—
—
2.7e+00
1.7e+00
cases:4.63%
controls:7.13%
—
—
—
—
—
—
—
—
cases:20.62%
controls:1.69%
cases:18.03%
controls:4.00%
5
77
103
1003
—
—
—
—
20
18
77
1046
11
35
50
841
EKG study
11524-6 [3013512]
-1.5e-01
6.9e-01
2.1e+00
—
2.2e+00
1.0e+00
-1.9e-01
cases:8.33%
controls:9.54%
cases:8.33%
controls:4.35%
cases:6.48%
controls:0.83%
—
—
cases:6.60%
controls:0.74%
cases:14.43%
controls:5.73%
cases:13.11%
controls:15.41%
9
103
99
977
9
47
99
1033
7
9
101
1071
—
7
8
99
1072
14
61
83
1003
8
135
53
741
Osmolality of Urine
2695-5 [3026782]
2.7e-01
1.4e+00
2.3e+00
—
—
1.8e+00
1.0e+00
cases:6.48%
controls:5.00%
cases:8.33%
controls:2.13%
cases:5.56%
controls:0.56%
—
—
—
—
cases:12.37%
controls:2.26%
cases:11.48%
controls:4.45%
7
54
101
1026
9
23
99
1057
6
6
102
1074
—
—
12
24
85
1040
7
39
54
837
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
-2.3e-01
1.2e+00
2.8e+00
—
—
8.8e-01
4.8e-01
cases:9.26%
controls:11.39%
cases:14.81%
controls:5.09%
cases:7.41%
controls:0.46%
—
—
—
—
cases:13.40%
controls:6.02%
cases:21.31%
controls:14.38%
10
123
98
957
16
55
92
1025
8
5
100
1075
—
—
13
64
84
1000
13
126
48
750
Tissue Pathology biopsy report
66121-5 [40768804]
9.2e-01
9.5e-01
—
1.0e+50
—
2.7e+00
1.2e+00
cases:17.59%
controls:7.87%
cases:5.56%
controls:2.22%
—
—
cases:25.00%
controls:0.00%
—
—
cases:25.77%
controls:2.16%
cases:24.59%
controls:8.68%
19
85
89
995
6
24
102
1056
—
27
0
81
1080
—
25
23
72
1041
15
76
46
800
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
-1.2e-01
—
2.2e+00
—
2.0e+00
1.5e+00
7.4e-01
cases:7.41%
controls:8.24%
—
—
cases:6.48%
controls:0.74%
—
—
cases:4.72%
controls:0.65%
cases:13.40%
controls:3.20%
cases:13.11%
controls:6.74%
8
89
100
991
—
7
8
101
1072
—
5
7
101
1073
13
34
84
1030
8
59
53
817
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
4.3e-01
4.6e-01
—
—
1.0e+50
2.5e+00
1.2e+00
cases:11.11%
controls:7.50%
cases:4.63%
controls:2.96%
—
—
—
—
cases:5.66%
controls:0.00%
cases:31.96%
controls:3.76%
cases:31.15%
controls:11.53%
12
81
96
999
5
32
103
1048
—
—
6
0
100
1080
31
40
66
1024
19
101
42
775
General anesthesia, balanced
WX408 [2001310808]
1.3e+00
-1.0e+50
—
—
—
2.5e+00
1.9e+00
cases:12.96%
controls:4.07%
cases:0.00%
controls:1.30%
—
—
—
—
—
—
cases:8.25%
controls:0.75%
cases:9.84%
controls:1.60%
14
44
94
1036
0
14
108
1066
—
—
—
8
8
89
1056
6
14
55
862
One hour or less
ZXE00 [2001311394]
8.2e-01
9.5e-01
—
—
—
2.0e+00
1.6e+00
cases:14.81%
controls:7.13%
cases:5.56%
controls:2.22%
—
—
—
—
—
—
cases:9.28%
controls:1.32%
cases:13.11%
controls:2.85%
16
77
92
1003
6
24
102
1056
—
—
—
9
14
88
1050
8
25
53
851
Coloscopy
UJF32 [2001305029]
7.8e-01
1.8e+00
—
—
—
—
1.8e+00
cases:8.33%
controls:3.98%
cases:10.19%
controls:1.76%
—
—
—
—
—
—
—
—
cases:18.03%
controls:3.42%
9
43
99
1037
11
19
97
1061
—
—
—
—
11
30
50
846
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
6.3e-01
8.4e-01
2.0e+00
—
2.6e+00
1.1e+00
7.4e-01
cases:17.59%
controls:10.19%
cases:13.89%
controls:6.48%
cases:4.63%
controls:0.65%
—
—
cases:5.66%
controls:0.46%
cases:16.49%
controls:6.11%
cases:34.43%
controls:20.09%
19
110
89
970
15
70
93
1010
5
7
103
1073
—
6
5
100
1075
16
65
81
999
21
176
40
700
Bacteria identified in Urine by Culture
630-4 [3026008]
2.1e-01
1.8e-01
2.1e+00
—
—
1.5e+00
7.8e-01
cases:8.33%
controls:6.85%
cases:4.63%
controls:3.89%
cases:7.41%
controls:0.93%
—
—
—
—
cases:15.46%
controls:3.95%
cases:22.95%
controls:11.99%
9
74
99
1006
5
42
103
1038
8
10
100
1070
—
—
15
42
82
1022
14
105
47
771
Elastase.pancreatic [Mass/mass] in Stool
25907-7 [3000570]
-1.0e+50
—
—
—
—
3.6e+00
2.1e+00
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
cases:14.43%
controls:0.47%
cases:8.20%
controls:1.03%
0
7
108
1073
—
—
—
—
14
5
83
1059
5
9
56
867
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
-1.2e-01
1.3e-01
—
—
2.4e+00
1.1e+00
7.5e-01
cases:7.41%
controls:8.24%
cases:6.48%
controls:5.74%
—
—
—
—
cases:4.72%
controls:0.46%
cases:15.46%
controls:5.83%
cases:29.51%
controls:16.55%
8
89
100
991
7
62
101
1018
—
—
5
5
101
1075
15
62
82
1002
18
145
43
731
Fractional oxyhemoglobin in Arterial blood
2714-4 [3014007]
—
—
—
1.0e+50
—
3.4e+00
—
—
—
—
—
—
—
cases:9.26%
controls:0.00%
—
—
cases:12.37%
controls:0.47%
—
—
—
—
—
10
0
98
1080
—
12
5
85
1059
—
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
1.2e-02
1.2e+00
—
—
—
2.1e+00
1.2e+00
cases:8.33%
controls:8.24%
cases:11.11%
controls:3.52%
—
—
—
—
—
—
cases:24.74%
controls:3.85%
cases:31.15%
controls:11.53%
9
89
99
991
12
38
96
1042
—
—
—
24
41
73
1023
19
101
42
775
Iron deficiency anaemia, unspecified
D50.9 [45605373]
3.2e+00
—
1.0e+50
—
—
2.1e+00
—
cases:10.19%
controls:0.46%
—
—
cases:6.48%
controls:0.00%
—
—
—
—
cases:5.15%
controls:0.66%
—
—
11
5
97
1075
—
7
0
101
1080
—
—
5
7
92
1057
—
Bicarbonate [Moles/volume] in Serum or Plasma
1963-8 [3016293]
—
—
—
—
—
3.1e+00
—
—
—
—
—
—
—
—
—
—
—
cases:11.34%
controls:0.56%
—
—
—
—
—
—
—
11
6
86
1058
—
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
3.9e-01
2.6e-02
4.6e-01
—
2.0e+00
1.1e+00
7.8e-01
cases:50.00%
controls:40.28%
cases:23.15%
controls:22.69%
cases:7.41%
controls:4.81%
—
—
cases:22.64%
controls:3.98%
cases:47.42%
controls:22.46%
cases:63.93%
controls:44.86%
54
435
54
645
25
245
83
835
8
52
100
1028
—
24
43
82
1037
46
239
51
825
39
393
22
483
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
-6.6e-02
1.1e+00
2.0e+00
—
—
-3.6e-01
3.4e-01
cases:23.15%
controls:24.35%
cases:27.78%
controls:11.30%
cases:12.04%
controls:1.85%
—
—
—
—
cases:8.25%
controls:11.47%
cases:37.70%
controls:30.14%
25
263
83
817
30
122
78
958
13
20
95
1060
—
—
8
122
89
942
23
264
38
612
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
6.2e-01
—
—
—
—
3.1e+00
1.0e+00
cases:5.56%
controls:3.06%
—
—
—
—
—
—
—
—
cases:12.37%
controls:0.66%
cases:9.84%
controls:3.77%
6
33
102
1047
—
—
—
—
12
7
85
1057
6
33
55
843
Oncology Clinic/Center
261QX0200X [38004268]
3.0e+00
1.0e+50
—
1.0e+50
—
—
—
cases:10.19%
controls:0.56%
cases:4.63%
controls:0.00%
—
—
cases:99.07%
controls:0.00%
—
—
—
—
—
—
11
6
97
1074
5
0
103
1080
—
107
0
1
1080
—
—
—
Laceration/cut
S18 [2002000983]
4.0e-01
1.8e-01
—
—
3.0e+00
1.2e+00
7.4e-01
cases:13.89%
controls:9.72%
cases:4.63%
controls:3.89%
—
—
—
—
cases:11.32%
controls:0.65%
cases:10.31%
controls:3.38%
cases:24.59%
controls:13.47%
15
105
93
975
5
42
103
1038
—
—
12
7
94
1073
10
36
87
1028
15
118
46
758
Bicarbonate [Moles/volume] standard in Arterial blood
19230-2 [3014218]
-1.0e+50
—
—
1.0e+50
—
2.9e+00
—
cases:0.00%
controls:0.56%
—
—
—
—
cases:8.33%
controls:0.00%
—
—
cases:8.25%
controls:0.47%
—
—
0
6
108
1074
—
—
9
0
99
1080
—
8
5
89
1059
—
Immunohistochemistry procedure
117617002 [4035726]
—
—
—
1.0e+50
—
—
2.9e+00
—
—
—
—
—
—
cases:18.52%
controls:0.00%
—
—
—
—
cases:9.84%
controls:0.57%
—
—
—
20
0
88
1080
—
—
6
5
55
871
Stomach Pathology biopsy report
66114-0 [40768797]
8.7e-01
2.9e+00
1.0e+50
1.0e+50
—
1.9e+00
—
cases:7.41%
controls:3.24%
cases:15.74%
controls:1.02%
cases:5.56%
controls:0.00%
cases:13.89%
controls:0.00%
—
—
cases:6.19%
controls:0.94%
—
—
8
35
100
1045
17
11
91
1069
6
0
102
1080
15
0
93
1080
—
6
10
91
1054
—
Physiotherapy
R4110 [2001310233]
5.1e-01
—
—
1.0e+50
—
2.9e+00
1.2e+00
cases:10.19%
controls:6.39%
—
—
—
—
cases:4.63%
controls:0.00%
—
—
cases:20.62%
controls:1.41%
cases:14.75%
controls:4.79%
11
69
97
1011
—
—
5
0
103
1080
—
20
15
77
1049
9
42
52
834
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
—
—
—
1.0e+50
—
2.9e+00
6.5e-01
—
—
—
—
—
—
cases:10.19%
controls:0.00%
—
—
cases:13.40%
controls:0.85%
cases:8.20%
controls:4.45%
—
—
—
11
0
97
1080
—
13
9
84
1055
5
39
56
837
Oxygen [Partial pressure] in Arterial blood
2703-7 [3027801]
—
—
—
1.0e+50
—
2.9e+00
6.5e-01
—
—
—
—
—
—
cases:10.19%
controls:0.00%
—
—
cases:13.40%
controls:0.85%
cases:8.20%
controls:4.45%
—
—
—
11
0
97
1080
—
13
9
84
1055
5
39
56
837
Carboxyhemoglobin/Hemoglobin.total in Arterial blood
2030-5 [3028653]
—
—
—
1.0e+50
—
2.9e+00
—
—
—
—
—
—
—
cases:9.26%
controls:0.00%
—
—
cases:9.28%
controls:0.56%
—
—
—
—
—
10
0
98
1080
—
9
6
88
1058
—
Methemoglobin/Hemoglobin.total in Arterial blood
2615-3 [3006217]
—
—
—
1.0e+50
—
2.9e+00
—
—
—
—
—
—
—
cases:9.26%
controls:0.00%
—
—
cases:9.28%
controls:0.56%
—
—
—
—
—
10
0
98
1080
—
9
6
88
1058
—
Base excess in Arterial blood by calculation
1925-7 [3003396]
—
—
—
1.0e+50
—
2.8e+00
6.8e-01
—
—
—
—
—
—
cases:10.19%
controls:0.00%
—
—
cases:13.40%
controls:0.94%
cases:8.20%
controls:4.34%
—
—
—
11
0
97
1080
—
13
10
84
1054
5
38
56
838
pH of Arterial blood
2744-1 [3019977]
—
—
—
1.0e+50
—
2.8e+00
7.0e-01
—
—
—
—
—
—
cases:10.19%
controls:0.00%
—
—
cases:13.40%
controls:0.94%
cases:8.20%
controls:4.22%
—
—
—
11
0
97
1080
—
13
10
84
1054
5
37
56
839
Norovirus RNA [Presence] in Stool by NAA with probe detection
7974-9 [3008909]
—
—
—
—
—
—
2.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.84%
controls:0.68%
—
—
—
—
—
—
6
6
55
870
fentanyl; nasal, sublingual, transdermal
N02AB03 [21604272]
—
—
—
—
—
—
2.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.20%
controls:0.57%
—
—
—
—
—
—
5
5
56
871
Palliative care
Z51.5 [45547323]
—
—
—
—
—
—
2.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.20%
controls:0.57%
—
—
—
—
—
—
5
5
56
871
Fever, unspecified
R50.9 [45582716]
—
—
—
—
—
2.7e+00
1.8e+00
—
—
—
—
—
—
—
—
—
—
cases:9.28%
controls:0.66%
cases:9.84%
controls:1.83%
—
—
—
—
—
9
7
88
1057
6
16
55
860
Oxygen capacity [Volume Fraction] in Arterial blood
59275-8 [40762366]
-1.0e+50
—
—
1.0e+50
—
2.7e+00
—
cases:0.00%
controls:0.65%
—
—
—
—
cases:7.41%
controls:0.00%
—
—
cases:9.28%
controls:0.66%
—
—
0
7
108
1073
—
—
8
0
100
1080
—
9
7
88
1057
—
Hemoglobin [Mass/volume] in Arterial blood
30313-1 [3002173]
—
—
—
1.0e+50
—
2.7e+00
—
—
—
—
—
—
—
cases:10.19%
controls:0.00%
—
—
cases:11.34%
controls:0.85%
—
—
—
—
—
11
0
97
1080
—
11
9
86
1055
—
Oxygen saturation in Arterial blood
2708-6 [3016502]
—
—
—
1.0e+50
—
2.7e+00
—
—
—
—
—
—
—
cases:10.19%
controls:0.00%
—
—
cases:12.37%
controls:0.94%
—
—
—
—
—
11
0
97
1080
—
12
10
85
1054
—
Urea [Moles/volume] in Serum or Plasma
22664-7 [3020779]
—
—
—
—
—
2.7e+00
—
—
—
—
—
—
—
—
—
—
—
cases:17.53%
controls:1.41%
—
—
—
—
—
—
—
17
15
80
1049
—
Folate [Moles/volume] in Serum or Plasma
14732-2 [3021960]
—
8.9e-01
—
—
—
1.6e+00
1.0e+00
—
—
cases:6.48%
controls:2.78%
—
—
—
—
—
—
cases:10.31%
controls:2.16%
cases:29.51%
controls:13.13%
—
7
30
101
1050
—
—
—
10
23
87
1041
18
115
43
761
Extensive abdominal CT
JN3BD [2001305556]
—
—
—
—
—
—
2.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.48%
controls:0.91%
—
—
—
—
—
—
7
8
54
868
Bicarbonate [Moles/volume] in Arterial blood
1960-4 [3008152]
—
—
—
—
—
2.6e+00
—
—
—
—
—
—
—
—
—
—
—
cases:6.19%
controls:0.47%
—
—
—
—
—
—
—
6
5
91
1059
—
sulfasalazine; oral, rectal
A07EC01 [21600663]
—
—
—
—
—
—
2.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.84%
controls:0.80%
—
—
—
—
—
—
6
7
55
869
Reticulocytes/Erythrocytes in Blood
4679-7 [3027945]
1.0e+00
2.6e+00
—
—
—
1.5e+00
—
cases:5.56%
controls:2.04%
cases:10.19%
controls:0.83%
—
—
—
—
—
—
cases:6.19%
controls:1.50%
—
—
6
22
102
1058
11
9
97
1071
—
—
—
6
16
91
1048
—
Calcium [Moles/volume] corrected for albumin in Serum or Plasma
29265-6 [3020059]
9.4e-01
—
—
—
1.0e+50
2.6e+00
9.0e-01
cases:8.33%
controls:3.43%
—
—
—
—
—
—
cases:5.66%
controls:0.00%
cases:23.71%
controls:2.26%
cases:18.03%
controls:8.22%
9
37
99
1043
—
—
—
6
0
100
1080
23
24
74
1040
11
72
50
804
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
6.8e-01
1.2e+00
—
—
—
2.6e+00
1.4e+00
cases:4.63%
controls:2.41%
cases:4.63%
controls:1.48%
—
—
—
—
—
—
cases:16.49%
controls:1.50%
cases:14.75%
controls:4.11%
5
26
103
1054
5
16
103
1064
—
—
—
16
16
81
1048
9
36
52
840
Flexible sigmoidoscopy with biopsy
UJF45 [2001305031]
—
—
—
—
—
—
2.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.20%
controls:0.68%
—
—
—
—
—
—
5
6
56
870
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
2.6e-01
2.3e-01
2.5e+00
—
—
1.2e+00
6.7e-01
cases:6.48%
controls:5.09%
cases:4.63%
controls:3.70%
cases:5.56%
controls:0.46%
—
—
—
—
cases:11.34%
controls:3.67%
cases:21.31%
controls:12.21%
7
55
101
1025
5
40
103
1040
6
5
102
1075
—
—
11
39
86
1025
13
107
48
769
Bacterial infection, unspecified
A49.9 [45590816]
—
-1.0e+50
—
—
—
2.5e+00
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
cases:9.28%
controls:0.85%
—
—
—
0
9
108
1071
—
—
—
9
9
88
1055
—
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
—
-1.0e+50
—
—
—
2.5e+00
1.1e+00
—
—
cases:0.00%
controls:1.02%
—
—
—
—
—
—
cases:8.25%
controls:0.75%
cases:8.20%
controls:2.85%
—
0
11
108
1069
—
—
—
8
8
89
1056
5
25
56
851
Infection following a procedure, not elsewhere classified
T81.4 [45575538]
—
-1.0e+50
—
—
—
2.4e+00
2.0e+00
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
cases:5.15%
controls:0.47%
cases:8.20%
controls:1.14%
—
0
8
108
1072
—
—
—
5
5
92
1059
5
10
56
866
Dentistry
C5 [903277]
—
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.20%
controls:0.80%
—
—
—
—
—
—
5
7
56
869
Type 2 diabetes mellitus, without complications
E11.9 [45561952]
3.0e-01
7.4e-01
2.3e+00
—
1.9e+00
4.8e-01
—
cases:10.19%
controls:7.78%
cases:8.33%
controls:4.17%
cases:5.56%
controls:0.56%
—
—
cases:4.72%
controls:0.74%
cases:7.22%
controls:4.61%
—
—
11
84
97
996
9
45
99
1035
6
6
102
1074
—
5
8
101
1072
7
49
90
1015
—
Epithelial cells.squamous [#/volume] in Urine by Automated count
51486-9 [3029879]
1.0e+00
1.7e+00
2.3e+00
—
—
1.7e+00
8.6e-01
cases:4.63%
controls:1.76%
cases:6.48%
controls:1.30%
cases:4.63%
controls:0.46%
—
—
—
—
cases:7.22%
controls:1.41%
cases:16.39%
controls:7.65%
5
19
103
1061
7
14
101
1066
5
5
103
1075
—
—
7
15
90
1049
10
67
51
809
Protein [Presence] in Urine by Test strip
20454-5 [3014051]
—
9.5e-01
2.3e+00
—
—
8.3e-01
6.9e-01
—
—
cases:5.56%
controls:2.22%
cases:4.63%
controls:0.46%
—
—
—
—
cases:7.22%
controls:3.29%
cases:21.31%
controls:11.99%
—
6
24
102
1056
5
5
103
1075
—
—
7
35
90
1029
13
105
48
771
ABO and Rh group [Type] in Blood
882-1 [3003694]
2.9e-01
1.5e+00
—
—
—
2.3e+00
1.0e+00
cases:4.63%
controls:3.52%
cases:5.56%
controls:1.30%
—
—
—
—
—
—
cases:11.34%
controls:1.22%
cases:14.75%
controls:5.94%
5
38
103
1042
6
14
102
1066
—
—
—
11
13
86
1051
9
52
52
824
Tissue transglutaminase IgA Ab [Units/volume] in Serum
31017-7 [3019050]
8.3e-01
2.3e+00
—
—
—
—
—
cases:8.33%
controls:3.80%
cases:9.26%
controls:1.02%
—
—
—
—
—
—
—
—
—
—
9
41
99
1039
10
11
98
1069
—
—
—
—
—
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
—
—
—
—
—
2.3e+00
3.7e-01
—
—
—
—
—
—
—
—
—
—
cases:12.37%
controls:1.41%
cases:8.20%
controls:5.82%
—
—
—
—
—
12
15
85
1049
5
51
56
825
Oxygen [Partial pressure] in Venous blood
2705-2 [3024354]
—
—
—
—
—
2.3e+00
6.8e-01
—
—
—
—
—
—
—
—
—
—
cases:9.28%
controls:1.03%
cases:8.20%
controls:4.34%
—
—
—
—
—
9
11
88
1053
5
38
56
838
Benign neoplasm: Colon, unspecified
D12.6 [45576377]
—
—
—
—
1.0e+50
—
2.3e+00
—
—
—
—
—
—
—
—
cases:4.72%
controls:0.00%
—
—
cases:8.20%
controls:0.91%
—
—
—
—
5
0
101
1080
—
5
8
56
868
Pain localized to upper abdomen
R10.1 [45568111]
—
2.2e+00
—
—
—
—
—
—
—
cases:9.26%
controls:1.11%
—
—
—
—
—
—
—
—
—
—
—
10
12
98
1068
—
—
—
—
—
Lactate [Moles/volume] in Serum or Plasma
2524-7 [3014111]
—
—
—
1.0e+50
—
2.2e+00
7.9e-01
—
—
—
—
—
—
cases:7.41%
controls:0.00%
—
—
cases:9.28%
controls:1.13%
cases:8.20%
controls:3.88%
—
—
—
8
0
100
1080
—
9
12
88
1052
5
34
56
842
IgA [Mass/volume] in Serum or Plasma
2458-8 [3007164]
1.1e+00
2.1e+00
—
—
—
—
—
cases:7.41%
controls:2.69%
cases:7.41%
controls:0.93%
—
—
—
—
—
—
—
—
—
—
8
29
100
1051
8
10
100
1070
—
—
—
—
—
pH of Venous blood
2746-6 [3012544]
—
—
—
—
—
2.1e+00
7.0e-01
—
—
—
—
—
—
—
—
—
—
cases:9.28%
controls:1.22%
cases:9.84%
controls:5.14%
—
—
—
—
—
9
13
88
1051
6
45
55
831
Carbon dioxide [Partial pressure] in Venous blood
2021-4 [3021447]
—
—
—
—
—
2.1e+00
7.0e-01
—
—
—
—
—
—
—
—
—
—
cases:9.28%
controls:1.22%
cases:9.84%
controls:5.14%
—
—
—
—
—
9
13
88
1051
6
45
55
831
amoxicillin and beta-lactamase inhibitor; oral, parenteral
J01CR02 [21602863]
6.4e-01
—
—
—
—
2.1e+00
6.3e-01
cases:12.96%
controls:7.31%
—
—
—
—
—
—
—
—
cases:14.43%
controls:2.07%
cases:9.84%
controls:5.48%
14
79
94
1001
—
—
—
—
14
22
83
1042
6
48
55
828
Abdominal ultrasound examination
JN3AE [2001305555]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.48%
controls:1.60%
—
—
—
—
—
—
7
14
54
862
Calprotectin [Mass/mass] in Stool
38445-3 [3048689]
—
2.0e+00
—
—
—
—
—
—
—
cases:9.26%
controls:1.30%
—
—
—
—
—
—
—
—
—
—
—
10
14
98
1066
—
—
—
—
—
Bacteria identified in Skin by Aerobe culture
620-5 [3007853]
—
—
—
—
—
2.0e+00
1.1e+00
—
—
—
—
—
—
—
—
—
—
cases:7.22%
controls:1.03%
cases:8.20%
controls:2.85%
—
—
—
—
—
7
11
90
1053
5
25
56
851
Base excess in Venous blood by calculation
1927-3 [3002032]
—
—
—
—
—
2.0e+00
6.8e-01
—
—
—
—
—
—
—
—
—
—
cases:8.25%
controls:1.22%
cases:9.84%
controls:5.25%
—
—
—
—
—
8
13
89
1051
6
46
55
830
Psychiatry
26 [38004469]
2.6e-01
—
—
—
—
2.0e+00
9.9e-01
cases:5.56%
controls:4.35%
—
—
—
—
—
—
—
—
cases:8.25%
controls:1.22%
cases:8.20%
controls:3.20%
6
47
102
1033
—
—
—
—
8
13
89
1051
5
28
56
848
Gas panel - Venous blood
24339-4 [3000991]
—
—
—
1.0e+50
—
1.9e+00
—
—
—
—
—
—
—
cases:7.41%
controls:0.00%
—
—
cases:7.22%
controls:1.13%
—
—
—
—
—
8
0
100
1080
—
7
12
90
1052
—
Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
34487-9 [3044938]
—
—
—
—
—
1.9e+00
1.2e+00
—
—
—
—
—
—
—
—
—
—
cases:8.25%
controls:1.32%
cases:16.39%
controls:5.48%
—
—
—
—
—
8
14
89
1050
10
48
51
828
insulin aspart; parenteral
A10AB05 [21600719]
1.2e+00
1.3e+00
—
—
-1.0e+50
1.9e+00
—
cases:4.63%
controls:1.39%
cases:5.56%
controls:1.57%
—
—
—
—
cases:0.00%
controls:0.46%
cases:9.28%
controls:1.50%
—
—
5
15
103
1065
6
17
102
1063
—
—
0
5
106
1075
9
16
88
1048
—
pH of Urine
2756-5 [3015736]
2.8e-01
5.5e-01
1.9e+00
—
—
5.8e-01
7.8e-01
cases:12.96%
controls:10.09%
cases:8.33%
controls:5.00%
cases:7.41%
controls:1.20%
—
—
—
—
cases:11.34%
controls:6.67%
cases:31.15%
controls:17.24%
14
109
94
971
9
54
99
1026
8
13
100
1067
—
—
11
71
86
993
19
151
42
725
Hypothyroidism, unspecified
E03.9 [45537945]
—
—
—
—
—
1.8e+00
1.9e+00
—
—
—
—
—
—
—
—
—
—
cases:5.15%
controls:0.85%
cases:11.48%
controls:1.94%
—
—
—
—
—
5
9
92
1055
7
17
54
859
insulin aspart; parenteral
A10AD05 [21600733]
1.2e+00
1.3e+00
—
—
-1.0e+50
1.8e+00
—
cases:4.63%
controls:1.39%
cases:5.56%
controls:1.57%
—
—
—
—
cases:0.00%
controls:0.46%
cases:9.28%
controls:1.60%
—
—
5
15
103
1065
6
17
102
1063
—
—
0
5
106
1075
9
17
88
1047
—
pH of Specimen
17433-4 [3019225]
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
cases:8.25%
controls:1.41%
—
—
—
—
—
—
—
8
15
89
1049
—
Urology
34 [38004474]
6.1e-01
1.3e+00
—
—
2.0e+00
1.8e+00
8.9e-01
cases:12.04%
controls:6.94%
cases:8.33%
controls:2.41%
—
—
—
—
cases:4.72%
controls:0.65%
cases:13.40%
controls:2.44%
cases:16.39%
controls:7.42%
13
75
95
1005
9
26
99
1054
—
—
5
7
101
1073
13
26
84
1038
10
65
51
811
Loss of teeth due to accident, extraction or local periodontal disease
K08.1 [45591573]
—
—
—
—
—
-1.0e+50
1.8e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.85%
cases:11.48%
controls:2.05%
—
—
—
—
—
0
9
97
1055
7
18
54
858
Epithelial cells.non-squamous [#/volume] in Urine by Automated count
51485-1 [3030306]
—
1.8e+00
—
—
—
1.6e+00
8.4e-01
—
—
cases:6.48%
controls:1.11%
—
—
—
—
—
—
cases:7.22%
controls:1.50%
cases:18.03%
controls:8.68%
—
7
12
101
1068
—
—
—
7
16
90
1048
11
76
50
800
potassium chloride; oral
A12BA01 [21600877]
5.0e-01
—
—
—
—
1.8e+00
8.2e-01
cases:4.63%
controls:2.87%
—
—
—
—
—
—
—
—
cases:8.25%
controls:1.50%
cases:8.20%
controls:3.77%
5
31
103
1049
—
—
—
—
8
16
89
1048
5
33
56
843
Scheduled procedure
ZXD10 [2001311387]
5.2e-01
—
—
—
—
1.7e+00
1.3e+00
cases:12.04%
controls:7.50%
—
—
—
—
—
—
—
—
cases:9.28%
controls:1.79%
cases:9.84%
controls:2.85%
13
81
95
999
—
—
—
—
9
19
88
1045
6
25
55
851
Endocrinology
46 [38004485]
—
1.2e+00
—
—
—
1.7e+00
8.6e-01
—
—
cases:5.56%
controls:1.76%
—
—
—
—
—
—
cases:8.25%
controls:1.60%
cases:8.20%
controls:3.65%
—
6
19
102
1061
—
—
—
8
17
89
1047
5
32
56
844
aciclovir; oral, parenteral
J05AB01 [21603131]
1.7e+00
—
—
—
—
—
—
cases:8.33%
controls:1.67%
—
—
—
—
—
—
—
—
—
—
—
—
9
18
99
1062
—
—
—
—
—
—
Respiratory and circulatory monitoring
WX700 [2001310817]
8.2e-01
—
—
—
—
—
1.7e+00
cases:6.48%
controls:2.96%
—
—
—
—
—
—
—
—
—
—
cases:13.11%
controls:2.74%
7
32
101
1048
—
—
—
—
—
8
24
53
852
Other specified counselling
Z71.8 [45581061]
-2.1e-02
—
—
—
—
1.6e+00
7.0e-01
cases:4.63%
controls:4.72%
—
—
—
—
—
—
—
—
cases:10.31%
controls:2.35%
cases:14.75%
controls:7.88%
5
51
103
1029
—
—
—
—
10
25
87
1039
9
69
52
807
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
1.1e-01
1.3e+00
—
—
—
1.5e+00
9.1e-01
cases:4.63%
controls:4.17%
cases:8.33%
controls:2.31%
—
—
—
—
—
—
cases:10.31%
controls:2.44%
cases:13.11%
controls:5.71%
5
45
103
1035
9
25
99
1055
—
—
—
10
26
87
1038
8
50
53
826
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
-1.7e-02
-2.8e-01
—
—
1.5e+00
1.5e-01
1.4e-02
cases:31.48%
controls:31.85%
cases:11.11%
controls:14.17%
—
—
—
—
cases:9.43%
controls:2.22%
cases:17.53%
controls:15.51%
cases:29.51%
controls:29.22%
34
344
74
736
12
153
96
927
—
—
10
24
96
1056
17
165
80
899
18
256
43
620
ibuprofen
R02AX02 [1588667]
-1.7e-02
-2.8e-01
—
—
1.5e+00
1.5e-01
1.4e-02
cases:31.48%
controls:31.85%
cases:11.11%
controls:14.17%
—
—
—
—
cases:9.43%
controls:2.22%
cases:17.53%
controls:15.51%
cases:29.51%
controls:29.22%
34
344
74
736
12
153
96
927
—
—
10
24
96
1056
17
165
80
899
18
256
43
620
Panorama tomography of teeth and jaws or similar X-ray examination
EB1HA [2001301913]
1.5e-01
—
—
—
—
1.5e+00
1.5e+00
cases:11.11%
controls:9.72%
—
—
—
—
—
—
—
—
cases:7.22%
controls:1.79%
cases:22.95%
controls:6.51%
12
105
96
975
—
—
—
—
7
19
90
1045
14
57
47
819
Hemoglobin A1c/Hemoglobin.total in Blood
4548-4 [3004410]
5.2e-02
3.0e-01
1.4e+00
—
9.9e-01
6.7e-02
-2.7e-01
cases:37.04%
controls:35.83%
cases:32.41%
controls:26.30%
cases:12.96%
controls:3.52%
—
—
cases:8.49%
controls:3.33%
cases:30.93%
controls:29.51%
cases:47.54%
controls:54.34%
40
387
68
693
35
284
73
796
14
38
94
1042
—
9
36
97
1044
30
314
67
750
29
476
32
400
Infiltration anesthesia
WX110 [2001310767]
1.1e-01
-1.5e-02
—
1.0e+50
—
1.4e+00
8.2e-01
cases:24.07%
controls:22.13%
cases:6.48%
controls:6.57%
—
—
cases:4.63%
controls:0.00%
—
—
cases:22.68%
controls:7.05%
cases:36.07%
controls:19.98%
26
239
82
841
7
71
101
1009
—
5
0
103
1080
—
22
75
75
989
22
175
39
701
Troponin I.cardiac [Mass/volume] in Serum or Plasma
10839-9 [3021337]
1.3e-01
1.1e+00
—
—
—
1.3e+00
1.1e+00
cases:5.56%
controls:4.91%
cases:7.41%
controls:2.59%
—
—
—
—
—
—
cases:11.34%
controls:3.29%
cases:19.67%
controls:7.88%
6
53
102
1027
8
28
100
1052
—
—
—
11
35
86
1029
12
69
49
807
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
2.3e-01
—
—
—
—
1.8e+00
1.3e+00
cases:8.33%
controls:6.76%
—
—
—
—
—
—
—
—
cases:7.22%
controls:1.32%
cases:19.67%
controls:6.28%
9
73
99
1007
—
—
—
—
7
14
90
1050
12
55
49
821
zopiclone; oral
N05CF01 [21604654]
2.5e-01
-2.6e-01
—
—
9.6e-01
1.1e+00
9.5e-01
cases:12.04%
controls:9.63%
cases:4.63%
controls:5.93%
—
—
—
—
cases:4.72%
controls:1.85%
cases:16.49%
controls:6.02%
cases:19.67%
controls:8.68%
13
104
95
976
5
64
103
1016
—
—
5
20
101
1060
16
64
81
1000
12
76
49
800
Pharmacy visit
OMOP4822462 [581458]
3.1e-01
1.3e-01
6.4e-01
1.0e+00
1.1e+00
1.1e+00
1.0e+50
cases:96.30%
controls:95.00%
cases:90.74%
controls:89.63%
cases:70.37%
controls:55.65%
cases:8.33%
controls:3.24%
cases:79.25%
controls:56.11%
cases:96.91%
controls:91.35%
cases:100.00%
controls:97.26%
104
1026
4
54
98
968
10
112
76
601
32
479
9
35
99
1045
84
606
22
474
94
972
3
92
61
852
0
24
Split tooth for reasons other than trauma
K03.82 [2000502700]
-1.0e+50
—
—
—
—
—
4.1e-01
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
cases:13.11%
controls:9.13%
0
6
108
1074
—
—
—
—
—
8
80
53
796
Parkinson's disease and comparable movement disrorders
110 [2001600110]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
0
5
61
871
celecoxib; oral
M01AH01 [21603992]
8.5e-01
—
—
—
—
-1.0e+50
-1.0e+50
cases:4.63%
controls:2.04%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
cases:0.00%
controls:0.80%
5
22
103
1058
—
—
—
—
0
6
97
1058
0
7
61
869
SMOKING - SMOKE2: no - SMOKE3: former - SMOKE5: former
SMOKING-2-2-4 [2002330109]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.39%
—
—
—
—
—
—
—
—
—
—
—
—
0
15
108
1065
—
—
—
—
—
—
covid-19, RNA-based vaccine
J07BN01 [954934]
1.6e-01
5.2e-02
—
—
—
2.2e-01
2.7e-02
cases:13.89%
controls:12.04%
cases:14.81%
controls:14.17%
—
—
—
—
—
—
cases:17.53%
controls:14.57%
cases:44.26%
controls:43.61%
15
130
93
950
16
153
92
927
—
—
—
17
155
80
909
27
382
34
494
Depressive episode
F32 [45595904]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
0
5
61
871
ipratropium bromide; nasal
R01AX03 [21603199]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
108
1074
—
—
—
—
—
—
amlodipine; oral
C08CA01 [21601747]
-6.8e-01
-3.9e-01
—
—
—
-2.8e-01
-9.5e-01
cases:9.26%
controls:16.76%
cases:9.26%
controls:13.06%
—
—
—
—
—
—
cases:10.31%
controls:13.16%
cases:8.20%
controls:18.72%
10
181
98
899
10
141
98
939
—
—
—
10
140
87
924
5
164
56
712
Bicarbonate [Moles/volume] in Capillary blood
1961-2 [3015235]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
108
1075
—
—
—
—
—
—
Extended examination of mouth
SAA03 [2001310276]
-2.0e-01
—
—
—
—
—
—
cases:7.41%
controls:8.89%
—
—
—
—
—
—
—
—
—
—
—
—
8
96
100
984
—
—
—
—
—
—
Carotid artery syndrome (hemispheric)
G45.1 [45576586]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
108
1071
—
—
—
—
—
—
Other medical or dental certificate
WZA90 [2001310883]
1.1e-01
—
—
—
—
-1.0e+50
1.2e+00
cases:5.56%
controls:5.00%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
cases:9.84%
controls:3.20%
6
54
102
1026
—
—
—
—
0
5
97
1059
6
28
55
848
Abnormal result investigation NOS
A91 [2002000224]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
0
7
61
869
Unspecified dementia
F03 [45566772]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
108
1075
—
—
—
—
—
—
Complement C4 [Mass/volume] in Serum or Plasma
4498-2 [3017766]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.74%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
0
8
108
1072
—
—
—
—
—
0
6
61
870
Other chronic renal failure
N18.8 [45534123]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
0
5
61
871
Microscopic observation [Identifier] in Isolate by Gram stain
87975-9 [36305247]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
108
1071
—
—
—
—
—
—
Sprain and strain of cervical spine
S13.4 [45573197]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
108
1075
—
—
—
—
—
—
Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
40987-0 [3043924]
—
—
—
—
—
1.7e+00
1.0e+00
—
—
—
—
—
—
—
—
—
—
cases:5.15%
controls:0.94%
cases:11.48%
controls:4.34%
—
—
—
—
—
5
10
92
1054
7
38
54
838
Persistent atrial fibrillation
I48.1 [45548021]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
9
61
867
Hyperglycaemia, unspecified
R73.9 [45602038]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
0
6
61
870
Issue of medical certificate
Z02.7 [45537613]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.74%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
0
8
108
1072
—
—
—
—
—
0
6
61
870
Photography of fundus of eye
XCK10 [2001301381]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
0
5
97
1059
—
Initiation, adjustment, discontinuation or repetition of medication
SPAT1253 [2001700354]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
—
—
—
—
0
8
108
1072
—
—
—
—
ticagrelor; oral
B01AC24 [40252640]
—
—
-1.0e+50
—
—
-1.0e+50
-1.0e+50
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
cases:0.00%
controls:0.75%
cases:0.00%
controls:0.80%
—
—
0
5
108
1075
—
—
0
8
97
1056
0
7
61
869
darbepoetin alfa; parenteral
B03XA02 [21601134]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
0
5
61
871
Apolipoprotein B/Apolipoprotein A-I [Percentile]
9340-1 [3011831]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.14%
—
—
—
—
—
—
0
10
61
866
Other and unspecified symptoms and signs involving cognitive functions and awareness
R41.8 [45534452]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
0
9
97
1055
—
Chronic gingivitis
K05.1 [45605912]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.20%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
0
13
108
1067
—
—
—
—
—
0
5
61
871
other preparations, combinations; ointment
C05AX03 [21601631]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.94%
—
—
—
—
—
—
0
17
61
859
Laparoscopy
JAH01 [2001304475]
—
—
—
—
1.0e+50
1.0e+50
—
—
—
—
—
—
—
—
—
cases:4.72%
controls:0.00%
cases:6.19%
controls:0.00%
—
—
—
—
—
—
5
0
101
1080
6
0
91
1064
—
General health counselling
SPAT1312 [2001700413]
-5.3e-02
5.6e-01
—
—
—
5.6e-01
5.0e-01
cases:7.41%
controls:7.78%
cases:4.63%
controls:2.69%
—
—
—
—
—
—
cases:5.15%
controls:3.01%
cases:8.20%
controls:5.14%
8
84
100
996
5
29
103
1051
—
—
—
5
32
92
1032
5
45
56
831
Open wound of scalp
S01.0 [45592468]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
0
8
108
1072
—
—
—
—
0
6
97
1058
—
Sequelae of cerebral infarction
I69.3 [45533476]
—
—
-1.0e+50
—
—
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
0
5
108
1075
—
—
0
9
97
1055
—
short-acting sulfonamides - combinations
J01EB20 [21602943]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.39%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.14%
0
15
108
1065
—
—
—
—
—
0
10
61
866
Vascular dementia, unspecified
F01.9 [45533058]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
0
5
61
871
budesonide; inhalant
R03BA02 [21603285]
3.2e-01
3.5e-01
—
—
—
—
5.7e-01
cases:8.33%
controls:6.20%
cases:5.56%
controls:3.98%
—
—
—
—
—
—
—
—
cases:8.20%
controls:4.79%
9
67
99
1013
6
43
102
1037
—
—
—
—
5
42
56
834
Sprain and strain of ankle
S93.4 [45550848]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
108
1072
—
—
—
—
—
—
Stomatognathic treatment, basic
SHA02 [2001310406]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.93%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
108
1070
—
—
—
—
—
—
Three-surface restoration
SFA30 [2001310360]
3.0e-01
4.2e-01
—
—
-1.0e+50
1.2e+00
2.9e-02
cases:15.74%
controls:12.13%
cases:6.48%
controls:4.35%
—
—
—
—
cases:0.00%
controls:0.56%
cases:9.28%
controls:2.91%
cases:11.48%
controls:11.19%
17
131
91
949
7
47
101
1033
—
—
0
6
106
1074
9
31
88
1033
7
98
54
778
Presence of external hearing-aid
Z97.4 [45542504]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
0
6
97
1058
—
Urinary frequency/urgency
U02 [2002001138]
7.9e-01
—
—
—
—
—
—
cases:5.56%
controls:2.59%
—
—
—
—
—
—
—
—
—
—
—
—
6
28
102
1052
—
—
—
—
—
—
semaglutide; oral, parenteral
A10BJ06 [1501778]
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.65%
—
—
—
—
—
—
cases:0.00%
controls:0.46%
cases:0.00%
controls:1.32%
cases:0.00%
controls:2.51%
0
7
108
1073
—
—
—
0
5
106
1075
0
14
97
1050
0
22
61
854
oxazepam; oral
N05BA04 [21604569]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
cases:0.00%
controls:0.93%
—
—
—
—
—
—
0
5
108
1075
—
0
10
106
1070
—
—
Tachycardia, unspecified
R00.0 [45606790]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
108
1075
—
—
—
—
—
—
Familial hypercholesterolaemia
E78.00 [2000501513]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.46%
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
0
5
108
1075
0
6
108
1074
—
—
—
—
0
5
61
871
Vertigo/dizziness
N17 [2002000728]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
0
9
108
1071
—
—
—
—
—
Gout
M10 [45533711]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.14%
—
—
—
—
—
—
0
10
61
866
Observation for other suspected diseases and conditions
Z03.89 [2000503757]
1.2e+00
—
—
—
—
—
—
cases:4.63%
controls:1.48%
—
—
—
—
—
—
—
—
—
—
—
—
5
16
103
1064
—
—
—
—
—
—
fluticasone furoate
R03BA09 [45893496]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.57%
—
—
—
—
—
—
cases:0.00%
controls:1.97%
—
—
—
0
17
108
1063
—
—
—
0
21
97
1043
—
Periodontal treatment by dental hygienist, very extensive
SDE04 [2001310352]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.13%
—
—
—
—
—
—
—
—
—
—
—
—
0
23
108
1057
—
—
—
—
—
—
Bruise/contusion
S16 [2002000981]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
0
7
108
1073
—
—
—
—
—
0
6
61
870
Implementation of physical therapy rehabilitation plan
SPAT1223 [2001700324]
-1.0e-01
—
-1.0e+50
—
-1.0e+50
—
—
cases:5.56%
controls:6.11%
—
—
cases:0.00%
controls:0.65%
—
—
cases:0.00%
controls:0.74%
—
—
—
—
6
66
102
1014
—
0
7
108
1073
—
0
8
106
1072
—
—
chlorhexidine, combinations
D08AC52 [21602208]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
cases:0.00%
controls:0.66%
cases:0.00%
controls:1.94%
—
0
8
108
1072
—
—
—
0
7
97
1057
0
17
61
859
Nummular dermatitis
L30.0 [45562535]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
108
1075
—
—
—
—
—
—
Type 1 diabetes mellitus, With ophthalmic complications
E10.3 [45552380]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
9
61
867
Neurological sympt/complt other
N29 [2002000734]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
108
1075
—
—
—
—
—
—
econazole; vaginal
G01AF05 [21602395]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
0
5
61
871
Ultrasound examination of upper part of abdomen
JN1AE [2001305517]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.30%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
0
14
108
1066
—
—
—
—
—
0
6
61
870
Mitral (valve) prolapse
I34.1 [45552788]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
0
7
108
1073
—
—
—
—
—
0
6
61
870
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Blood
47598-8 [3048816]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.02%
cases:0.00%
controls:0.74%
—
—
—
—
—
—
—
—
—
—
0
11
108
1069
0
8
108
1072
—
—
—
—
—
Neoplasm of uncertain or unknown behaviour: Other digestive organs
D37.7 [45552349]
—
—
1.0e+50
—
—
—
—
—
—
—
—
cases:4.63%
controls:0.00%
—
—
—
—
—
—
—
—
—
—
5
0
103
1080
—
—
—
—
Chronic apical periodontitis
K04.5 [45586691]
4.9e-01
-1.0e+50
—
—
—
-1.0e+50
4.3e-01
cases:8.33%
controls:5.28%
cases:0.00%
controls:2.31%
—
—
—
—
—
—
cases:0.00%
controls:1.13%
cases:8.20%
controls:5.48%
9
57
99
1023
0
25
108
1055
—
—
—
0
12
97
1052
5
48
56
828
Home Visit
OMOP4822459 [581476]
—
—
-1.0e+50
-1.0e+50
—
4.9e-01
6.7e-01
—
—
—
—
cases:0.00%
controls:3.06%
cases:0.00%
controls:0.74%
—
—
cases:9.28%
controls:5.92%
cases:24.59%
controls:14.27%
—
—
0
33
108
1047
0
8
108
1072
—
9
63
88
1001
15
125
46
751
tacrolimus
D11AH01 [21602338]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.83%
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
0
9
108
1071
0
6
108
1074
—
—
—
—
—
Specialised imaging for glaucoma
CS5Z4 [2001301479]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
cases:0.00%
controls:1.03%
0
6
108
1074
—
—
—
—
0
6
97
1058
0
9
61
867
Repair of inguinal hernia using prosthetic material
JAB30 [2001304393]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
—
0
6
108
1074
—
—
—
—
—
Paralysis/weakness
N18 [2002000729]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
0
5
61
871
loratadine; oral
R06AX13 [21603514]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
—
0
11
97
1053
—
Ischaemic heart dis without angina
K76 [2002000603]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
108
1073
—
—
—
—
—
—
piroxicam; oral, parenteral, rectal
M01AC01 [21603961]
4.2e-01
—
—
—
—
—
—
cases:6.48%
controls:4.35%
—
—
—
—
—
—
—
—
—
—
—
—
7
47
101
1033
—
—
—
—
—
—
pH of Blood
11558-4 [3010421]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
0
5
108
1075
—
—
—
—
—
0
5
61
871
General and Unspecified, Preventive immunization/medic
A44 [2002000178]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
0
5
61
871
finasteride; oral
D11AX10 [21602350]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.11%
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
12
108
1068
—
0
5
106
1075
—
—
Other dorsalgia
M54.8 [45538790]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
108
1075
—
—
—
—
—
—
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
313 [2001600274]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
0
7
108
1073
—
—
—
—
—
0
7
61
869
Rheumatoid/seropositive arthritis
L88 [2002000707]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
0
5
108
1075
—
—
—
—
—
Presence of prosthetic heart valve
Z95.2 [45542495]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
0
6
108
1074
—
—
—
—
—
0
7
61
869
Folate [Moles/volume] in Red Blood Cells
14731-4 [3019309]
8.4e-01
1.1e+00
—
—
—
1.7e+00
9.6e-01
cases:13.89%
controls:6.48%
cases:6.48%
controls:2.22%
—
—
—
—
—
—
cases:6.19%
controls:1.22%
cases:9.84%
controls:4.00%
15
70
93
1010
7
24
101
1056
—
—
—
6
13
91
1051
6
35
55
841
Cervical spine MRI examination with high intensity magnet
NA1BG [2001306990]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
108
1074
—
—
—
—
—
—
phenylpropanolamine, combinations; oral
R01BA51 [21603212]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.39%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.14%
0
15
108
1065
—
—
—
—
—
0
10
61
866
Otitis externa, unspecified
H60.9 [45605727]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
14
108
1066
—
—
—
—
—
—
Stomatognathic treatment, simple
SHA01 [2001310405]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
8
61
868
Apolipoprotein B [Mass/volume] in Serum or Plasma
1884-6 [3014791]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.37%
—
—
—
—
—
—
0
12
61
864
SMOKING - SMOKE2: yes - SMOKE3: current - SMOKE5: Unspecified
SMOKING-1-1-0 [2002330116]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
0
7
108
1073
—
—
—
—
—
Other Alzheimer disease
G30.8 [45605532]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
0
6
61
870
Superficial injury of head, part unspecified
S00.9 [45587557]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
0
6
61
870
Preparing and fitting the occlusal splint in the mouth
SHB00 [2001310410]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.02%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
108
1069
—
—
—
—
—
—
Abrasion dentifrice of teeth
K03.11 [2000502670]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
108
1075
—
—
—
—
—
—
nortriptyline; oral, parenteral
N06AA10 [21604697]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
cases:0.00%
controls:0.57%
—
—
—
—
—
0
6
97
1058
0
5
61
871
lorazepam; oral, parenteral, sublingual
N05BA06 [21604571]
-1.0e+50
-1.0e+50
-1.0e+50
—
-1.0e+50
—
-1.0e+50
cases:0.00%
controls:1.30%
cases:0.00%
controls:1.02%
cases:0.00%
controls:0.74%
—
—
cases:0.00%
controls:0.65%
—
—
cases:0.00%
controls:1.48%
0
14
108
1066
0
11
108
1069
0
8
108
1072
—
0
7
106
1073
—
0
13
61
863
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD)/1.73 sq M
77147-7 [46236952]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
19
108
1061
—
—
—
—
—
—
Ankle symptom/complaint
L16 [2002000640]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
cases:0.00%
controls:2.05%
—
—
—
—
—
0
7
97
1057
0
18
61
858
dexamethasone
S01BA01 [21603618]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.93%
—
—
—
—
—
—
—
—
—
—
—
0
10
108
1070
—
—
—
—
—
Rheumatoid factor [Units/volume] in Serum or Plasma
11572-5 [3021614]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.76%
—
—
—
—
—
—
—
—
—
—
—
0
19
108
1061
—
—
—
—
—
Capsular endoscopy
UJF92 [2001305032]
—
1.0e+50
—
—
—
—
—
—
—
cases:5.56%
controls:0.00%
—
—
—
—
—
—
—
—
—
—
—
6
0
102
1080
—
—
—
—
—
Smooth muscle Ab [Titer] in Serum
8095-2 [3007566]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
0
6
61
870
Headache
R51.80 [2000503603]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
0
7
108
1073
—
—
—
0
5
97
1059
—
Other local analgesia
WX199 [2001310775]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
8
61
868
CPAP therapy
WX723 [2001310826]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.14%
—
—
—
—
—
—
0
10
61
866
Impacted cerumen
H61.2 [45562307]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
0
5
108
1075
—
—
—
—
0
7
61
869
acetylsalicylic acid; oral, parenteral, rectal
N02BA01 [21604305]
—
-1.0e+50
-1.0e+50
—
-1.0e+50
—
—
—
—
cases:0.00%
controls:1.39%
cases:0.00%
controls:0.46%
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
0
15
108
1065
0
5
108
1075
—
0
5
106
1075
—
—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
34
23
21.03
40.04
1.6
1.2
—
—
—
0
0
47
67
11.57
34.45
7.2
1.8
0.19
0.22
g/l
1.20
47
56
86
382
6.93
18.04
4.9
2.3
—
—
estimate
—
0
0
50
142
5.66
17.78
1.8
1.3
—
—
—
0
0
69
268
5.29
16.58
4.6
2.0
—
—
—
0
0
83
386
5.82
15.64
15.6
3.5
32.45
35.62
g/l
4.44
83
361
46
134
5.21
15.60
14.7
5.9
102.96
103.84
mmol/l
0.44
46
134
65
259
4.74
14.65
7.0
3.7
—
—
—
0
0
45
144
4.62
13.30
5.9
2.0
0.80
0.82
mmol/l
0.99
45
133
23
22
12.92
13.03
1.5
1.3
150.73
324.00
ug/g
2.38
18
12
36
98
4.99
12.98
1.8
1.3
—
—
—
0
0
60
258
3.95
11.47
3.2
1.6
—
—
—
0
0
29
74
4.98
11.16
1.5
1.1
—
—
—
0
0
29
79
4.64
10.26
4.7
4.3
8.58
11.62
mmol/l
1.08
29
73
34
115
3.84
8.91
12.3
6.6
7.41
7.41
ph
0.07
17
66
80
472
3.61
8.46
10.8
5.4
1.18
1.21
mmol/l
2.35
74
406
82
495
3.65
8.28
22.2
5.6
3.61
4.29
e9/l
2.33
75
423
36
135
3.49
8.00
3.4
1.9
—
—
—
0
0
78
478
3.22
7.25
16.0
14.8
1.18
1.30
inr
2.05
69
399
52
257
2.96
7.12
14.5
5.1
—
—
—
0
0
25
81
3.71
6.84
12.6
8.0
—
—
—
0
0
53
286
2.66
5.88
5.4
4.9
—
—
—
0
0
67
406
2.69
5.87
5.3
5.0
8.71
9.05
%
0.33
62
377
65
403
2.52
5.21
5.3
5.0
0.70
0.64
%
0.33
60
372
8
6
14.24
5.16
2.1
1.3
22.50
30.17
umol/l
—
8
6
41
206
2.59
5.13
1.6
1.3
—
—
—
0
0
50
280
2.45
4.94
4.0
3.1
0.41
0.29
e6/l
0.26
41
199
55
322
2.43
4.92
4.0
3.3
17.22
264.17
e6/l
0.64
45
243
9
11
8.79
4.66
3.7
5.4
11.41
12.04
mg/l
—
9
11
33
159
2.54
4.42
3.3
3.1
1.61
2.05
e6/l
0.17
16
70
58
362
2.29
4.32
4.4
3.9
980.82
107.13
e6/l
0.44
45
254
48
282
2.25
4.08
5.8
3.0
7.39
7.40
ph
0.87
37
192
68
464
2.24
3.96
5.3
5.3
1.56
1.82
e9/l
1.75
58
407
67
455
2.23
3.94
5.3
5.2
0.59
0.60
e9/l
0.13
56
386
36
190
2.34
3.91
2.0
1.9
1475.81
1228.51
nmol/l
0.52
31
146
67
460
2.18
3.77
5.3
5.2
0.04
0.04
e9/l
0.51
55
391
68
473
2.16
3.66
5.5
5.1
0.18
0.21
e9/l
0.75
57
406
24
109
2.54
3.58
4.8
2.9
7.38
7.39
ph
0.20
13
62
10
23
4.68
3.40
6.2
1.7
61.00
15.80
u/ml
—
10
23
13
39
3.64
3.36
1.2
1.2
—
—
—
0
0
59
400
2.04
3.28
21.4
10.1
0.01
0.00
e9/l
0.49
47
323
24
115
2.39
3.19
1.4
1.7
—
—
—
0
0
45
287
1.97
2.88
3.7
2.9
—
—
—
0
0
5
6
8.65
2.77
3.0
2.7
1.80
0.83
index
—
5
6
63
456
1.90
2.72
3.0
2.2
92.05
97.61
pmol/l
0.44
42
225
10
30
3.56
2.68
4.9
1.7
—
—
—
0
0
75
889
0.50
2.67
4.4
5.8
4.23
4.50
mmol/l
1.16
67
822
28
154
2.10
2.66
1.8
1.5
29.27
29.08
s
0.09
28
147
34
202
1.99
2.63
4.1
3.7
108.77
297.08
ng/l
0.63
26
166
75
884
0.51
2.47
4.3
5.7
1.34
1.46
mmol/l
1.57
66
809
19
338
0.47
2.35
3.5
3.7
—
—
—
0
0
19
99
2.11
2.06
1.4
1.6
—
—
—
0
0
14
64
2.36
2.04
10.4
3.3
—
—
—
0
0
5
11
4.71
1.96
1.0
1.1
—
—
—
0
0
5
11
4.71
1.96
2.4
1.3
1.72
2.06
mmol/l
—
5
11
5
11
4.71
1.96
3.0
2.5
14.00
13.50
index
—
5
6
5
11
4.71
1.96
1.2
1.6
12.91
15.44
ug/l
—
5
11
79
902
0.55
1.93
5.1
6.7
2.49
2.59
mmol/l
0.39
69
830
73
850
0.57
1.89
4.0
4.8
1.24
1.30
mmol/l
0.27
64
770
14
68
2.21
1.79
3.6
2.8
2.00
0.68
%
—
6
14
15
76
2.13
1.74
1.3
1.3
—
—
—
0
0
10
43
2.46
1.64
1.3
1.4
—
—
—
0
0
12
57
2.24
1.62
3.9
2.2
0.68
0.61
%
0.34
12
57
13
64
2.17
1.62
3.1
2.6
0.80
0.21
%
—
5
14
13
66
2.10
1.50
3.8
2.8
0.40
0.08
%
—
5
12
12
59
2.16
1.50
3.9
2.2
0.81
1.24
%
1.79
12
59
13
74
1.86
1.12
1.3
1.3
—
—
—
0
0
26
181
1.57
1.12
1.4
1.4
2.54
2.97
g/l
0.49
14
102
49
393
1.45
1.08
5.9
3.5
6.06
6.13
ph
0.19
31
219
12
68
1.86
1.05
1.3
1.5
—
—
—
0
0
27
193
1.53
1.04
3.8
3.9
—
—
—
0
0
29
217
1.46
0.90
2.0
1.8
363.05
412.81
pmol/l
0.63
22
176
34
267
1.40
0.81
5.1
3.0
—
0.00
—
0
7
76
830
0.72
0.77
5.6
5.4
2.01
1.95
mu/l
0.14
69
753
90
950
0.70
0.64
74.6
22.2
119.63
135.95
g/l
15.96
90
941
5
30
1.70
0.62
1.0
1.2
—
—
—
0
0
90
949
0.70
0.61
73.7
22.0
29.77
30.41
pg
2.57
90
940
90
949
0.70
0.61
76.3
22.5
36.55
40.48
%
12.66
90
940
90
949
0.70
0.61
74.1
22.1
262.48
240.72
e9/l
2.38
90
934
90
948
0.71
0.59
73.8
22.1
90.59
91.45
fl
1.04
90
939
32
262
1.31
0.58
2.0
2.5
341.07
364.72
umol/l
0.49
27
225
31
372
0.77
0.56
3.5
3.4
7.29
7.51
mmol/l
0.09
25
310
9
64
1.44
0.53
5.7
3.0
—
—
—
0
0
11
76
1.50
0.50
3.3
2.9
—
—
—
0
0
84
887
0.77
0.48
5.2
5.6
6.47
6.12
mmol/l
0.98
78
807
8
59
1.38
0.42
2.1
4.8
4.79
5.10
kpa
—
8
54
32
370
0.81
0.41
3.6
3.5
71.03
38.62
mg/l
0.33
23
247
90
938
0.77
0.40
64.7
20.0
77.76
81.61
umol/l
0.43
90
928
76
711
1.23
0.39
61.7
17.1
14.89
13.68
%
6.17
76
703
9
67
1.37
0.39
1.2
1.3
—
—
—
0
0
54
493
1.19
0.35
6.7
3.7
0.00
0.00
estimate
-0.00
13
101
35
393
0.84
0.32
5.0
4.5
1.89
2.03
ug/l
0.16
28
346
12
94
1.31
0.29
1.3
1.5
—
—
—
0
0
54
501
1.15
0.27
6.7
3.7
0.00
0.00
estimate
-0.00
14
103
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
54
507
1.13
0.21
6.6
3.7
0.00
0.08
estimate
0.79
13
93
90
873
1.18
0.21
49.4
14.2
37.54
23.73
mg/l
4.08
90
709
6
47
1.29
0.21
1.0
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.5
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.4
—
—
—
0
0
0
13
0.00
0.21
0.0
1.5
—
—
—
0
0
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
0
14
0.00
0.20
0.0
2.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
90
923
0.86
0.18
61.3
18.8
3.94
4.01
mmol/l
1.47
90
905
35
376
0.90
0.16
4.4
4.3
13.66
6.31
mg/mmol
0.37
25
242
90
921
0.87
0.16
62.2
18.7
138.17
139.74
mmol/l
5.87
90
903
9
78
1.17
0.16
2.9
2.5
5.78
5.99
ph
—
9
58
24
222
1.10
0.11
2.6
2.9
0.97
0.80
ug/l
0.36
14
146
67
689
0.93
0.10
4.6
4.2
14.40
15.00
pmol/l
1.54
60
619
89
904
0.92
0.08
43.5
12.9
—
—
—
0
0
29
279
1.05
0.04
6.2
3.7
0.00
0.00
estimate
-0.00
13
94
11
103
1.08
0.02
1.7
2.6
5.40
6.15
ug/l
0.15
11
90
38
374
1.02
0.00
7.8
3.6
0.00
0.03
estimate
0.49
12
76
26
263
0.99
0.00
7.4
3.2
0.00
0.00
estimate
-0.00
11
76
44
435
1.02
0.00
5.4
4.1
18.39
48.09
ng/l
2.62
34
334
0
8
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
76.71
—
0
7
0
9
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
7
71
0.98
-0.00
3.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
21.17
—
0
6
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.2
—
2.60
—
0
6
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
175.47
—
0
6
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
1440.00
—
0
5

Mortality – FinRegistry

↥

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

Relationships between endpoints

↥

Index endpoint: C3_SMALL_INTESTINE_ADENO – Adenocarcinoma of small intestine

GWS hits: -

This endpoint is excluded from FinRegistry analyses (omitted endpoint).